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In aging the loss of bone mass goes along with a decline of 17-estradiol (E2) 
and Growth Hormone (GH), which are known to be bone anabolic factors. 
Recent evidence demonstrated in several cell lines an interplay between E2 and 
GH at a post receptor level. I thus evaluated the possible cross-talk between 
these two hormones in human osteoblast cells (hOBs) in primary culture and 
in their mesenchymal precursors (hMSCs).  
E2 (10-8M) given 60 min before GH (5ng/ml) enhanced both GH intracellular 
pathway in hOBs and the transcription of the evaluated GH target genes 
involved in osteoblast activity and matrix deposition, osteopontin (OPN), bone 
sialoprotein (BSP) and insulin like growth factor 2 (IGF2). E2 effects occurred 
by decreasing the protein levels of SOCS2, one of the main GH signaling 
inhibitors, through an increase in SOCS2 ubiquitination and consequent 
degradation. This effect was blunted by pre-treating the cells with the 
proteasome inhibitor MG132 (5µM). Interestingly this effect did not involve an 
E2 mediated genomic activity as Actinomycin D (5µM) pre-treatment did not 
prevent E2 modulation of SOCS2 levels (Bolamperti S. et al., 2013). Further 
experiments demonstrated that this short term effect on SOCS2 levels was 
maintained over time: after 3h of E2 treatment there was still a decrease in 
SOCS2 levels. Yet, at this time point, the effect occurred via an inhibition of the 
transcription of SOCS2 gene. The fact that E2 negative regulation of the GH 
inhibitor SOCS2 involves an initially rapid protein degradation maintained for 
a longer time by a decrease in its gene expression strengthens the importance 
and the physiological relevance of this modulation for osteoblast activity. I was 
therefore interested to investigate whether or not two SERMs often used in 
clinics, Tamoxifen (Tam) and Raloxifene (Ral), share the same effect on GH 
signaling as E2. Cells treated with Tam (10-10M) or Ral (10-8M) 60 min before 
GH showed a trend to increase STAT5 phosphorylation even though reaching 
statistical significance, despite an observed reduction of SOCS2 levels with the 
SERMs alone. After 3h treatment no modulation of SOCS2 transcription was 
detected with either Tam, or Ral. These data suggest that despite their general 
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estrogen agonistic properties on bone, none of the two drugs displayed the 
same features as E2. 
The combined effect of E2 and GH was evaluated also in mesenchymal stem 
cells (MSCs) obtained from human bones. The cells were first tested for plastic 
adherence, for differentiation capability towards adipocytes or osteoblasts, and 
for the positivity to CD73, CD105, and CD90 following an NIH protocol. In 
these osteoblast precursors, pretreatment of E2 60 min before GH, increased 
STAT5 phosphorylation induced by GH and decreased SOCS2 levels, as shown 
in hOBs. Considering the lack of information about GH action in stromal 
precursors, we evaluated GH action in the isolated hMSCs, focusing on its 
possible role in both osteogenesis and adipogenesis. The results showed that                                                                                                                                                                                                                                                                     
long term GH treatment (5ng/ml, 14 days, 3 times/week) increased early 
osteogenic genes and prevented adipogenesis in the isolated hMSCs. Given the 
important role of microRNAs in MSC commitment to osteoblastogenesis or 
adipogenesis, I analized if GH was able to increase miR-22 and miR-29c, 
considered amongst the main regulators of osteoblastogenesis or decrease 
miR-204, which is a regulator of adipogenesis. 
                                                                                                                                                
GH was able to upregulate the transcription of miR-22 and miR-29c, without 
affecting miR-204. E2 per se inhibited their transcription and, in the combined 
treatment with GH, E2 pre-treatment was able to inhibit the stimulatory effect 
of GH on miR22 and miR29c. In conclusion the study has shown a relevant 
hormone to hormone interaction; hence E2 can locally modulate GH activity 
potentiating its cellular signaling in osteoblasts and in their stromal 
precursors. In osteoblasts the increase in the activity of the GH signal 
transducers reflects an increase in the transcription of GH responsive genes 
involved in the regulation of the deposition and the turnover of minerals and in 
the control of osteoblasts and osteoclasts metabolism (Gehron Robey and 
Boskey, 2006). In mesenchymal stromal cells the E2 potentiating effect of GH 
signaling was not accompanied by a positive effect on miRNA expressions. This 
could be due to the strong inhibitory effect that E2 per se exerts on the 
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evaluated miRNAs. Thus it can be suggested that the combined treatment of 
hMSCs with E2 and GH involves different mechanisms of the two hormones on 
microRNAs.  
The data from the present study suggest that circulating estrogen levels should 
be considered in the management of GH replacement therapy in GH deficiency. 
Since the E2-GH cross talk is not shared by SERMs, the positive effect of E2 on 
GH signaling should be taken into account while developing new estrogen 
receptor modulators molecules.  
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1.1 BONE TISSUE AND BONES 
“Formation of the skeletal system is one of the hallmarks that distinguish 
vertebrates from invertebrates. In higher vertebrates the skeleton contains 
cartilage and mainly bone” (Yang, 2013). 
Bone tissue comprises the largest portion of the body’s connective tissue mass, 
but unlike other connective tissues, bone matrix (mineral, collagen, water, 
non-collagenous proteins, and lipids) is physiologically mineralized and has the 
unique property of being constantly regenerated throughout life by specific 
cell-types (Boskey & Gehron, 2013). 
Considering its composition, bone tissue can be divided in woven bone or 
lamellar bone (Fig 1.1.1). The former is immature bone, non-mineralized, 
constituted only by collagen fibers and therefore very elastic, present during 
embryonic development, or soon after fractures. The latter is instead richer in 
mineral content and usually replaces the woven bone. Lamellar bone appears 
for the first time during the third trimester of gestation, and is filled with many 
collagen fibers parallel to other fibers in the same layer (lamellae) thus giving 
origin to several parallel fibers columns, forming the so called osteons. Osteons 
have in the middle the haversian canal, a tube around narrow channels in 
between the lamellae, able to contain up to two capillaries and nerve fibers. In 
cross-sections the lamellae run in opposite directions in alternating layers, a 
peculiarity that allows bone to resist torsion forces. In the lamellar bone it is 
possible to distinguish the compact or cortical bone and the trabecular or 
cancellous bone. The two differ for the tridimensional orientation of the 
lamellae, but not for the composition. Generally the hard outer layer of bones 
is composed of cortical bone with few gaps inside with porosity around 5–30%. 
The cortical compartment gives bones their smooth, white, and solid 
appearance, and accounts for the 80% of the total bone mass of the adult 
skeleton. The interior of the bone is filled of trabecular tissue, composed of a 
porous network of lamellae (porosity around 30–90%), that due to its structure, 
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allows room for blood vessels and marrow. Trabecular bone accounts for the 
remaining 20% of the total bone mass but has nearly ten times the surface 
area of the compact bone. 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.1.1 Schematic image of a cross-section through a layer of cortical and cancellous bone. 
Adapted from Gray 1918 
 
In humans the adult skeleton is composed of 206 bones, which are covered 
outside and inside by two connective tissue membranes called periosteum and 
endosteum, respectively. The periosteum allows the longitudinal growth and 
protects the inner bone structure from traumas, whereas the endosteum,which 
is composed of a single layer of osteoprogenitor cells, is deputed to bone 
formation. Differing in shape, size, and functions, bones are divided in long, 
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short and flat bones. Long bones are longer than wider and are composed by a 
shaft called diaphysis and by two far ends, the epiphyses. These bones are 
almost made of cortical and trabecular bone. The diaphysis cavity (medullary 
cavity) contains the bone marrow. Short bones have only a thin layer of 
compact bone surrounding a cancellous interior and they are cube-shaped (e.g. 
wrist and ankle). The flat bones are thinner than the short ones and slightly 
curved. They are made of two parallel layers of cortical bone and with a a layer 
of trabecular bone between them (e.g. skull and sternum). 
 
Besides the well-known properties of protection of internal organs, 
hematopoiesis, physical support of the motor apparatus, bones are endocrine 
organs deeply involved in the regulation and control of the whole body 
metabolism. They produce indeed body growth factors (i.e. IGFs, BMPs, TGFs), 
are fat and mineral storages, as well as the controllers of calcium and 
phosphate metabolism and the deputies to buffer the blood against excessive 
changes in the physiological range of pH.  
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1.2 BONE CELLS 
The cells developing the various bone structures are the bone-resorbing 
osteoclasts, responsible of the digestion of bone matrix with the consequent 
release of minerals and signals factors; the mesenchymal stem/stromal cells, 
responsible for the expansion and healing of the skeletal tissue; the bone-
forming osteoblasts, responsible for matrix production and mineralization, 
which can either become osteocytes once embedded in their own-made matrix, 
or undergo apoptosis or  quiescence becoming bone lining cells. 
 
 
 
OSTEOCLASTS 
Osteoclasts are multi-nucleated cells with a diameter comprised between 20 
and 200 micron. They derive from the hematopoietic stem cells and 
macrophage lineage precursors.   
Osteoclastogenesis is driven by two essential cytokines: RANKL (Receptor 
Activator for Nuclear Factor κ B Ligand) and M-CSF (Macrophage-colony 
stimulating factor) (Boyle et al., 2003; Pixley et al., 2004). RANKL is member of 
the TNF family and it is necessary for the priming of osteoclasts precursors, 
whereas M-CSF contribute to the survival and proliferation. The production of 
these cytokines by osteoblasts, present either in soluble form or anchored to 
the matrix, is tightly regulated by several factors and it is dependent on the 
amount of osteoblast in the tissue. Upon stimuli as parathyroid hormone (PTH) 
or vitamin D (VITD) osteoblasts triggers osteoclastogenesis by secreting both 
M-CSF and RANKL or by exposing the latter on the membrane. Monocytes 
have the specific receptors, c-fms for M-CSF and RANK (Receptor Activator for 
Nuclear Factor κ B) for RANKL. Interestingly osteoblasts also secrete 
Osteoprotegerin (OPG,  a specific inhibitor of RANKL which competes for RANK 
(Kostenuik et al., 2001). The balance between RANKL, and OPG is responsible 
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for osteoclastogenesis activation and consequently for bone turnover. Other 
cytokines responsible for osteoclasts development are IL-1, IL-2, IL-3, IL-6, IL-
11, LIF (leukemia inhibitor factor) TNFs, oncostatin M, TGF-beta. Inhibitors are 
instead IL-4, IL-10, IL-18, INFγ and calcitonin, whose role is to induce 
retraction of mature osteoclast and quiescence. 
Osteoclasts are often located in little lacunae (Howship lacunae) in which they 
secret acids and proteolytic enzymes able to digest both collagen and the 
inorganic matrix, solubilizing the minerals thus inducing bone resorption 
(Baron et al., 1989). The osteoclats activity develops in three different phases: 
adhesion to matrix, creation of a pH acid environment, digestion of the matrix. 
The first step is mediated by integrins receptor. Once the cells have adhered to 
the matrix, they start protruding podosomes. A proton pump on the plasma 
membrane allows the acidification of the space within the podosomes ring, 
with the consequence of a local environment at pH 4.5, which is ideal for 
minerals solubility. The resorption process is physiologically relevant during 
bone repair and remodeling: a dysfunction can cause a severe human disease 
called osteopetrosis ,whose feature is the excess of bone (Teitelbaum et al., 
2003).   
A physiological bone turnover is necessary for the maintenance of bone 
mechano-properties. The turnover is usually activated either by micro-lesions 
or by homeostatic mineral needs. After the erosion of matrix by osteoclasts, 
osteoblasts migrate to the resorption site and start producing matrix to fill the 
Howship lacunae. As soon as the matrix reaches the right thickness it is 
mineralized by the deposition of calcium-phosphate crystals. All the cells 
involved in the whole process, both osteoclasts and osteoclasts, form a BMU 
(basic multicellular unit). These temporary bone anatomic structures, which 
derive from precursors resident in the bone marrow, completely disappear 
upon programmed apoptosis after the fulfillment of their duties. The process of 
bone resorption coupled with matrix apposition is the basis of bone 
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remodeling. In humans it covers a period up to 6-9 months (Parfitt et al., 
1994). 
 
 
 
 
MESENCHYMAL STEM/STROMAL CELLS 
The Mesenchymal Stem Cells (MSCs) are the multipotent stem cells that give 
origin to the skeletal tissue. During development they form bone either by 
differentiating directly into osteoblasts in the intramembranous osteogenesis 
process or through endochondral osteogenesis in which they differentiate to 
chondrocytes with the formation of a cartilage template, ossified then by 
osteoblast (Yang 2013). In the adult skeleton MSCs give rise to several different 
cell types, as osteoblasts, chondrocytes, adipocytes, and myoblasts (Caplan et 
al., 1991, 2001; Pittinger et al., 1999) 
 
 
 
 
 
 
 
 
 
Fig 1.2.1 MSCs multi-lineage differentiation, modified from Takedaet al.(2009) 
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The osteogenic precursors were first reported by Friedenstein and colleagues in 
1968 as in vitro spindle shaped, plastic-adherent, fibroblastic-like cells of the 
adult bone marrow, able to reconstitute in vivo the hematopoietic environment. 
In addition they showed that these cells could differentiate to bone and form 
colony forming unit (CFU-F) in vitro (Friedenstein et al., 1968, 1974). These 
experiments demonstrated for the first time the presence of a new cell type in 
the bone marrow stroma endowed with the potential of generating bone tissue. 
Based largely on these works, in 1988 it was postulated the existence of a 
stromal stem cell maintaining the marrow microenvironment as the 
hematopoietic stem cell maintains hematopoiesis (Owen &Friedenstein, 1988). 
However, convincing data to support the “stemness” were not forthcoming and 
it began a debate whether this MSC truly qualify a stem cell endowed of self-
renewal properties and asymmetric division (Horwizt et al., 2000). Although a 
bona fide mesenchymal stem cell may reside within the adherent cell in the 
marrow compartment, the International Society for Cellular Therapy (ISCT) has 
recommended that these spindle-shaped, plastic-adherent cells derived from 
adult organisms should be termed “mesenchymal stromal cells” (avoiding the 
necessity to change the acronym MSCs) unless the capacity of self-renewal is 
proven in vivo(Hortwiz et al., 2005).  
To better define their phenotype, the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy proposed three 
minimal criteria to define human MSCs. First, MSCs must be plastic-adherent 
when maintained in standard culture conditions. Second, MSCs must express 
CD105,CD73 and CD90, and lack expression of CD45, CD34, or in general of 
the hematopoietic markers. Third, MSCs must differentiate to osteoblasts, 
adipocytes and chondroblasts in vitro (Dominici et al., 2006). Considering that 
the characterization of these cells is in constant evolution, nowadays it is 
under debate if the above criteria can still be considered valid, especially as 
regards the surface markers expression (Keating et al., 2012). However it is 
commonly accepted however that this population is very heterogeneous and 
only the 20-50% of plastic adherent cells represent multipotent MSCs, whereas 
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the remaining cells are a mixture of bipotential and unipotential cells (Muraglia 
et al., 2000). 
Commitment of mesenchymal progenitors to different lineages is regulated by 
many hints coming from the local tissue microenvironment. It is known that 
there is an inverse reciprocal correlation between osteoblastogenesis and 
adipogenesis, with factors stimulating one of the two processes and inhibiting 
the other, resulting in increased osteoblastogenesis and decreased 
adipogenesis (Nuttal & Gimble, 2004).It has been proposed that bipotential 
osteoblast–adipocyte precursors form an intermediate in the process of 
commitment to these two lineages (Hasegawa et al., 2008). Two families of 
growth factors are at the moment the most studied due to their peculiarity to 
stimulate both osteoblastic and adipocytic differentiation: the Wnt (a 
portmanteau of Wingless and integration 1) family and the bone morphogenetic 
proteins (BMPs). As regards the Wnts Liu and colleagues demonstrated that 
they can favour osteogenic commitment in basal medium by inhibiting MSCs 
commitment into adipocytes, while inhibiting osteoblast differentiation in 
osteogenic conditions (Liu et al., 2009). Similarly BMPshave been shown to 
promote either adipogenesis (Sottile et al., 2000) or osteogenesis (Pereira et al., 
2002) depending on the expression and availability of other differentiation 
factors. In addition the above described pathways GH, IGFs, estrogens, 
glucocorticoids, leptin are also involved in MSCs commitment. 
PPAR-γ2 and the members of the CCAAT/enhancer binding protein (C/EBPs) 
are the major transcription factors activated during the adipogenic 
differentiation process. PPAR-γ2 is recognized as an essential transcriptional 
regulator of both adipocyte differentiation and lipid storage in mature 
adipocytes (Tontonoz et al., 2008), being its expression restricted only to this 
cell type (Bruedigam et al., 2008; Bruedigam et al., 2010). PPAR-γ2 
overexpression in fibroblasts can stimulate adipogenesis (Tontonoz et al., 
1994), whereas the KO results in the embryonic stem cells incapacity of 
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differentiation into adipocytes. Expression of PPAR-γ2 is regulated by C/EBP 
family of transcription factors, in particular by C/EBP-a. C/EBP is target of 
PPAR-γ2, thus creating a self-reinforcing regulatory loop (Tontonoz et al., 
2008). C/EBPs can be induced by adipogenic hormones, like glucocorticoids 
and adiponectin. (The transcription factors and pathways involved in 
osteoblasts differentiation will be discussed in the following osteoblasts 
session). 
A recent and new field of investigation concerns the role of microRNAs 
(miRNAs). These are short 18-25 nucleotides long  non-coding RNAs, that 
regulate protein expression by binding to the 3-UTR of target messenger RNAs 
and promoting degradation of the target mRNAs or avoiding their translation 
(Erson et al., 2008).  MiRNA expression patterns differ in MSC progenitors or 
fully differentiated cells, suggesting that miRNAs are highly relevant in MSC 
lineage decisions. Indeed, high or low expression levels of specific miRNAs may 
be a prerequisite for the commitment and differentiation of MSCs into specific 
lineages (Guo et al., 2011).  
In human MSCs under osteogenic commitment miR-22 was found to be up-
regulated and being a positive modulator (Huang et al., 2012). MiR-138 is 
instead inhibitory for osteoblastic differentiation (Eskildsen et al., 2008). MiR-
204 (Huang et al., 2010) and miR- 143 (Esau et al., 2004) promotes adipogenic 
commitment. 
 
 
OSTEOBLASTS 
Osteoblasts are cube-shaped cells, juxtaposing one next to each other. Once 
closely connected they start producing bone matrix, forming the so called 
mineralization front. Osteoblasts features are synthetizing and secreting matrix 
components as collagen type I, vitamin K-dependent proteins, osteocalcin, 
osteonectin, bone sialoprotein, osteopontin (proteins fundamental for 
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anchoring cells during matrix deposition), proteoglycans, and alkaline 
phosphatase, the enzyme responsible for bone mineralization. 
Osteoblasts maturation and functions are controlled by of specific stage-
dependent transcription factors.  The master regulator of MSCs differentiation 
towards the osteoblastic lineage is Runx releated protein 2 (RUNX2). RUNX2 is 
expressed in MSCs during skeletal fetal development and after birth it remains 
active during the whole osteoblast maturation (Karsenty et al., 2002). For these 
reasons its deficiency leads to the formation of a skeleton devoid of osteoblasts 
(Komori et al., 1997 Otto et al., 1997). RUNX2 was first found as a factor 
binding to an osteoblast specific cis-acting element in the promoter of 
Osteocalcin (Ducy et al., 1997), but consensus elements for RUNX2 have been 
also found in the promoters of many other oteoblastic genes,  as osteopontin, 
bone sialoprotein, alkaline phosphatase and the chain I-α of collagen type 1.  
RUNX2 activity is however in mature/late stage osteoblasts inhibitory 
(Maruyama et al., 2007, Liu et al., 2001), suggesting that this factor is 
necessary for the maintenance of osteoblasts in a more immature stage 
(Komori et al., 2006). A second master regulator of osteoblast differentiation, 
downstream RUNX2, is osterix (Osx). Osx is a zinc finger transcription factor 
belonging to the SP family, specifically expressed in osteoblasts, and required 
for bone formation (Nakashima et al., 2002). Overexpression in MSCs results 
in an increase in alkaline phosphatase activity and osteocalcin expression with 
a parallel increase in newly formed bone (Tu et al., 2007; Wang et al., 2013). 
Other two transcription factors important in the osteoblast maturation process 
are  ATF4 (activating transcription factor 4) and AP1 (activator protein 1). 
ATF4-deficiency decreased bone formation (Yang et al., 2004a), while forced 
accumulation of ATF4 induced osteoblastic genes expression even in non-
osseous cells (Yang et al., 2004b). Its anabolic effect is fulfilled through the 
binding to RUNX2 favouring osteocalcin expression (Xiao et al., 2005).  
The AP-1 proteins promote bone formation by binding physically to the 
promoters of several genes like osteocalcin, collagenase-3 (MMP13), bone 
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sialoprotein, and alkaline phosphatase, (Owen et al., 1990), regulating in this 
way their expression. 
 
 
 
 
 
Fig 1.2.2 Osteogenesis, modified from Fakhry et al. (2013) 
 
Factors that have a role in modulating the above described gene regulators are 
hormones like estrogens and growth hormone (that will be discussed further 
more in detail), BMPs (bone morphogetics proteins) TGF- β, FGF-2,vitamin D or 
parathyroid hormone (PTH). PTH can exert its anabolic effect on bone by 
activating simultaneously RUNX2 (Krishnan et al., 2003), Osx and inhibiting 
PPARγ (Wang et al., 2006) meanwhile being one of the principal activator of the 
AP1 complex. 
Not only hormones are involved in osteoblast differentiation, but also 
mechanical loading and the canonical Wnt pathway, which acts via the 
activation of the transcriptional factor β-catenin. The canonical Wnt activation 
occurs upon binding of the secreted Wnt glycoproteins to both one of the 
seven-helix-receptors of the frizzled family and the co-receptorsLrp5 or Lrp6.  
At the steady-state catenin is usually phosphorylated and degraded. Upon 
Wnt stimulation or also PTH stimulation (Tobimatsu et al, 2006), catenin is 
released from the degradation complex and accumulates in the cytoplasm as 
unphosphorylated form. It then translocates into the nucleus where it binds 
the TCF/LEF complex and activates the transcription of bone anabolic genes, 
i.e. osteoprotegerin (OPG) or RUNX2.  
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catenin deletion in MSCs and early osteoblasts prevents the differentiation 
along the osteogenic lineage (Day et al., 2005) and two recent large genome-
wide association studies identified Lrp5 as one of the highly significant genes 
associated with the bone mineral density (BMD) (Richards et al., 2008; van 
Meurs et al.,  2008). Mutations in the Lrp5 domain responsible of the binding, 
to dickkopf1 (Dkk1), a major inhibitor of the pathway, are associated with high 
bone mass (Boyden et al., 2002), confirming the key role of Wnt in maintaining 
it.  
Several microRNAs are involved in the osteogenic process. Among these worth 
of remark are miR-141, an inhibitor of osteoblasts differentiation and miR-210 
which is known to increase the transcription of both Osx and ALP by inhibiting 
a repressor of osteoblast differentiation (Miyazono K et al., 2005). The 
osteogenic commitment is also promoted by the up-regulation of miR-29 family 
and is negatively affected when it is knocked down. Validated targets for miR-
29 include several proteins that are inhibitors of osteoblast differentiation, 
such as histone deacetylase (HDAC)4 or TGFβ3 (Li et al., 2009). It was recently 
reported that canonical Wnt signaling rapidly induces the expression of both 
miR-29a and miR-29c (Kapinas et al., 2009). 
After the maturation process one third of the osteoblasts become osteocytes, 
one third bone lining cells, whereas the remaining undergo apoptosis. 
 
 
 
OSTEOCYTES 
The matrix secretion by osteoblasts is usually polarized towards the surface 
and with regular intermittent interval towards other directions. In this way the 
osteoblasts take distance one from each other, being embedded in the matrix. 
At the end of this secretory phase the osteoblast starts slowing down its 
metabolic activity, sits in matrix cavities, called lacunae, and becomes an 
osteocyte.  
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Fig 1.2.3 : SEM microphotograph (275X) at the middiaphyseal level of a metatarsal bone 
showing the methylmethacrylate casts of osteocyte lacunae and canaliculi. Periosteal 
and endosteal surfaces are to the left and right, respectivel ( Rubinacci et al., 1998) 
 
Osteocytes represents around the 90% of the cells present in bone. They are 
characterized by the presence on the outer membrane of long dendrites, which 
allow the cells to take nutrients from the circulation as well as releasing their 
secreted factors by going through the bone canaliculi. The factors released by 
dendrites are mainly matrix molecules or signals regulating bone and calcium 
homeostasis. At the far ends of the dendrites there are several gap junctions 
necessary for cell-cell communication between oteocytes and osteocytes-
osteoblats. A feature of osteocytes is that they are the body mechano-sensors, 
able to transduce the mechanical stimulus into an electric or biochemical 
signal (Rubinacci et al., 2003). In the presence of a micro-lesion they can 
activate bone remodeling by secreting RANKL (Mulcahy et al., 2011) and they 
can regulate osteoblast activity and maturation through the production and 
secretion of a soluble inhibitor of Wnt pathway, sclerostin (SOST). SOST by 
binding to LRP5/6 prevents the activation of the intracellular signal (Burgers 
and Williams, 2013)  
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In humans osteocytes live many years, also decades. In bone of the elderly it is 
possible to find some empty lacunae, marker of osteocytes death, suggesting 
that with aging they undergo programmed apoptosis. 
BONE LINING CELLS 
Once the maturation process ends some osteoblasts stop their activity, reduce 
the volume of their organelles and transform from cube-shaped cells to long 
flat cells, the so called bone lining cells. Not much is known about their 
physiological role. It is generally thought that they mediate communication 
between the various bone cells and blood vessels. Recently it has been shown 
that bone lining cells have the capacity of de-differentiate into osteoblast upon 
PTH stimulation (Kim et al., 2012) 
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1.3 OSTEOPOROSIS AND AGING 
More than 10 years ago, in 2000, around 200 million people were estimated 
being affected of osteoporosis (Dennison et al., 2000).  
Osteoporosis is a chronic skeletal disease, predominantly of aging, which 
affects particularly postmenopausal women but also elder men. Aging process 
is generally characterized by a gradually deterioration over time of homeostatic 
processes, leading to functional decline and increased risk for disease and 
death. Metabolically, aging is characterized by insulin resistance, and 
consequent changes in body composition; physiological declines in growth 
hormone (GH), insulin-like growth factor-1 (IGF-1), and sex steroids, and by an 
increase in the metabolic waste, the reactive oxygen species (ROS) (Barzilai et 
al., 2012). 
The economic burdens related to osteoporosis/osteoporotic fractures are 
significant. In the United States, based on the data from 2005, osteoporosis 
health care costs were c.a.17 billion dollars. These expenses are expected to 
increase by around 50% by 2025 (Komm et al., 2012). 
 
The pathogenesis of osteoporosis is as complex as the network of diverse 
stimuli determining the strength of the skeleton (Rosen &Raid, 2013). 
Commonly it is defined as low bone mineral density (decreased bone mass per 
volume unit of anatomical bone) associated with skeletal fractures secondary 
to minimal or no trauma, most often involving spine hip and forearm. The 
decrease in bone mineral density is the consequence of an unbalanced bone 
remodeling process, with higher bone resorption than bone formation. The 
microarchitecture of bone, especially the trabecular, is deeply impaired (Follet 
et al., 2011). As suggested by two epidemiological studies in both genders the 
decrease in bone mass starts soon after thirties and it is not correlated to 
changes in sex hormones levels, whose decline is later in life (Looker et al., 
1998; Riggs et al., 2008).  
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Nevertheless in women, compared to men, the loss of trabecular bone at the 
spine quickly accelerates after the menopause, as does the rate of fractures at 
the wrist and hip (Khosla S et al, 2005); attesting the positive role of estrogens 
on skeletal homeostasis. Cortical bone begins to decline after the age of 50 in 
both sexes.  
Strong evidence for a pivotal contribution of aging to fractures was highlighted 
already 20 years ago by the work of Hui et al. (Hui et al., 1988), showing that 
in subjects with the same BMD, but with  20-yr of difference in age, there is a 
4-fold increase in fracture risk in the older. During aging it occurs for example 
a deterioration of matrix proteins independent of hormonal status. Collagen 
type I undergoes severe changes leading to a structural impairment, as the loss 
of cross-linking between the component chains (Bailey & Knott 1999), with a 
consequent weakness of bone structure.   
Despite being a major negative determinant of aging and lifespan (Giorgio et 
al.,  2007; Russell et al., 2007; Lu et al., 2008) ROS cannot be avoided if living 
in an oxygen rich environment. In the cell the main sources of ROS are the 
mitochondria respiratory chain process and the fatty acid oxidation. ROS 
production can be induced by inflammatory cytokines and growth factors as 
well as external stimuli coming from the environment, i.e. UV light, or ionizing 
radiation. The administration of antioxidants to patients negatively regulates 
bone resorption with a positive effect on bone mass (Sanders et al., 2007; 
Pasco et al., 2006). Human clinical studies found indeed a correlation between 
the increase in oxidative stress and the decrease in BMD (Sánchez-Rodríguez 
et al., 2007;Oh et al., 2007; Altindag et al., 2008;) confirming  previous pre-
clinical data showing the occurrence of osteoporotic fractures upon OS damage 
in mice models of premature aging (Tyneret al., 2002; De Boer et al., J 2002). 
Considering the prospective of bone loss in aging, osteoporosis can be 
considered one of the many factors responsible for the compromised bone 
strength that predisposes to an increased risk of fracture in a more general 
and multifactorial fragility syndrome (Manolagas, 2010).   
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OSTEOPOROSIS TREATMENTS  
The aim of osteoporosis treatments is the prevention of fractures. Since the 
bone remodeling is unbalanced with an increase in bone resorption, the risk of 
fractures can be reduced either by inhibiting the resorption or by stimulating 
the formation. Due to the limitation of the current treatments, the bone 
research field is focused on finding novel antiresorptives and anabolics 
therapeutics.  
The current anabolic treatments are PTH, sclerostin antibodies (phase III 
clinical trials) and some selective estrogen receptor modulators, (SERMS). Daily 
injections of PTH stimulate immature osteoblasts to become bone-forming 
osteoblasts with an increase in matrix production. After 6-9 months this 
increase in osteoblasts drives a coupled increase in osteoclasts with a 
consequent loss in therapeutic effect (Rosen, 2013). SERMs application is 
usually restricted to specific pathological conditions, as osteoporotic women 
with a high risk of invasive breast cancer, due to the side effects on other 
apparatuses (Masimov et al., 2013). 
The common antiresorptive drugs are bisphosphonates and RANKL antibody.  
Bisphosphonates bind the matrix and prevent osteoclast resorption and induce 
osteoclasts apoptosis (Drake at al., 2008) RANKL antibodies inhibit 
osteclastogenesis by sequestering RANKL.  
Blocking bone resorption is crucial for preventing the worsening of 
osteoporosis. However, the usage of antiresorptive drugs as unique 
osteoporosis treatment can lead to the inhibition of the physiological bone 
turnover, thus affecting bone quality. Moreover preventing osteoclasts activity 
is not sufficient to restore a normal BMD.  
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1.4 GROWTH HORMONE 
Growth hormone (GH) is a circulating hormone with a half-life of 20-30 min 
whose blood concentrations range between 1 and 5-10 ng/ml. It is secreted 
from the pituitary gland following circadian cycles and its secretion is 
regulated by GHRH (growth hormone releasing hormone) and somatostatin, 
which are produced by hypothalamus. The former by binding to its specific 
receptor on the pituitary gland, favours GH production activating the 
transcription factors PROP1 and PIT1 (Potapov et al., 2006); the latter inhibits 
GH release thus determining the temporary windows of its activity. One of the 
major stimuli for GHRH production is hypoglycemia, which can be triggered i.e. 
by insulin administration or fasting. Others are intense physical activity, fever, 
stress, histamine, thyroxin, and serotonin.  
GH is produced throughout life, however over 30s its levels start decreasing of 
1% each year (Hermann et al. 2001). It is secreted as a mixture of different 
molecular variants. The most frequent form is a polypeptide of 191 amino 
acids, characterized by the bending of a single chain to form two rings linked 
together by di-sulfuric bridges. Two molecules of GH can also dimerize. Dimers 
can be present both in blood and the pituitary gland (Lewis, 1984).The coding 
gene for GH is located on the 17thchromosome and is called GH1. It situated in 
a cluster with somatotropin A and B (CSH1 e CSH2),placental growth factor 
(gh2) and CSH related genes. They all derive from a common ancestral 
precursor after duplication events, with identity of around 95% (Chen et al., 
1989). Despite the common structure (5 exons separated by 4 introns), GH1is 
the only one expressed in the pituitary gland, and the others are produced in 
the placenta. New-born from GH deficient mums have normal weight and 
length. (Rimoin et al.,1966). The responsiveness to the hormone starts 
gradually increasing after birth, with a parallel increase in GH receptor in 
peripheral tissues (Gluckman et al., 1983; Maes et al., 1983). 
As regards to GH biological effects, GH administration to hypophysectomized 
rats positively modulates nitrogen, phosphate, magnesium and potassium 
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metabolisms, skeletal and soft tissues growth. Effects of growth hormone on 
body different tissue can so generally be summarized as anabolic. 
 
GROWTH HORMONE AND BONE 
Among the anabolic effects on the body, the one on the skeletal development is 
the most known. GH is responsible of increasing height during childhood and 
it is important to maintain bone mass and homeostasis in the adults (Giustina 
et al. 2008). Congenital GH deficiency in humans and laboratory animals 
results in decreased bone growth and osteopenia (Ohlsson et al., 1998) 
In 1957 Salmon and Daughaday performed a key experiment in the field: they 
noticed that normal serum stimulated the incorporation of S14 in rat cartilage, 
whereas GH per se had no effect. These observations induced the authors to 
postulate that GH has no direct effects in stimulating growth processes in vitro 
and in vivo, but these should be mediated by something downstream GH, 
present in serum. They called these unknown factors somatomedin (Sms). The 
name was then changed in IGF1 and IGF2 (Insulin like growth factors), due to 
their insulin like properties (Blundell et al., 1978). During embryonic 
development IGFs are fundamental, but act in a GH independent manner 
(Woods et al., 1996), whereas in the post-natal life their action on bone 
longitudinal growth is always associated to GH (Isaksson et al., 1987). IGF1 
and IGF2 represent ca the 90% of the low kiloDalton protein from serum and 
are produced by the liver upon GH stimulation. Once produced they are 
released in the circulation system, where they can also bind to specific IGF 
binding proteins called IGF-BP (Zapf et al., 1975; Schwander et al., 1983). The 
role of the IGF-BP is to regulate IGFs availability and to increase their plasma 
half-life from 10 min to 3-4 hours. IGFs role is to promote proliferation and cell 
differentiation. They stimulate osteoblasts activity, favouring bone mass 
increase (Froesch et al., 1976). 
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In 1982 the concept that GH mediates its effect only through IGFs was revised 
by Isaksson and colleagues who showed that in vivo local administration of 
human GH to hypophysectomized rats resulted in accelerated longitudinal 
bone growth. Following these experiments other groups demonstrated a direct 
effect of growth hormone in favouring osteoblasts proliferation (Slootveg et al 
1988), due to the presence of the GH receptor (GHR) on the cells (Morales et 
al., 2000). The expression of GHR is regulated by GH through a IGF1-mediated 
down-regulation (Leung et al., 1996) 
Another important role of GH is the modulation of the osteoblast-osteoclast 
coupling, which occur through the stimulation of the OPG production and 
secretion in the local environment (Mrak et al., 2007). 
A recent field under investigation is the role of GH in modulating MSCs 
commitment since GHRs are expressed by bone marrow MSCs (Kassem et al., 
1994). There are in vivo evidences that bone marrow adipocytes are increased 
in number and size in GH deficiency dwarf rats (Gevers et al., 2002) and that 
GH suppresses bone marrow lipid accumulation (Menagh et al., 2010). 
Similarly to GH, IGF1 levels inversely correlate with bone marrow adiposity 
both in animals (Rosen et al., 2004) and in humans (Bredella et al., 2011).  
 
 
GROWTH HORMONE AND AGING 
During aging there is a progressive decline in GH secretion. In elder men can 
be even 20 fold less than in younger men (Ryall et al. 2008). The diminished 
GH secretion is not dependent on the pituitary gland, but it is the result of still 
unknown changes in the hypothalamus with the consequence of decreased 
GHRH and increased somatostatin (Veldhuis et al., 1996). As GH declines, 
IGF1 production and IGF1 systemic release are reduced (Landin-Wilhelmsen et 
al. 1994). The impairment of the GH/IGF1 axis correlates with a loss of BMD 
(Bohannon 1997) and bone itself , while aging, becomes less responsive to 
IGF1(Kveiborg et al. 2000). Pffeilschifter and colleagues showed that to elicit a 
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normal response to IGF1 it is necessary to use higher doses of the hormone 
when stimulating osteoblasts derived from elder patients compared to 
osteoblasts derived from younger ones (Pfeilschifter et al. 1993). These studies 
suggest that low circulating IGF1 and negative modifications of the GH/IGF1 
axismay play an important role in the age-related affection of the skeleton 
system (Perrini et al., 2010). 
 
 
GROWTH HORMONE SIGNALLING  
GH exerts its action by binding to its specific receptor (GHR) present on the cell 
membrane. GHR is free of any enzymatic activity as the other members of the 
family of cytokines receptor type 1. It is characterized by an extracellular 
domain for the binding of GH, a single chain transmembrane helix, and an 
intracellular domain composed of  two different motives, box1 and box 2, 
which able to bind both Janus Kinase 2 (JAK2) and the SH2 (Src Homologus)-
domain proteins (Brooks et al., 2007). The signal transduction (Fig. 1.4.1) 
starts when GH binds to the extracellular domain of its receptor. Through 
crystallographic experiments it was shown that each single GH molecule binds 
simultaneously two GHRs, in two asymmetric sites, probably causing the 
receptor dimerization (de Vos et al., 1992). However recent data support the 
hypothesis that the receptor is already present in membrane as a dimer(Gent 
et al., 2002; Brown et al., 2005). In accordance with Brown and colleagues, GH 
binds these pre-cast dimers causing a consequent rotation of the intracellular 
domain. Since each cytoplasmic tail binds two molecules of JAK2, the 
conformational change is needed to get them closer, thus allowing their cross-
phosphorylation. The kinases are activated and can then phosphorylate the 
receptor, allowing the recruitment of SH2 or PTB (Phospho-tyrosine binding) 
proteins, and triggering the activation of three different pathways: 
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1. JAK/STAT  
2. MAPKs  
3. PI3K/AKT 
 
 
 
1. JAK/STAT PATHWAY  
This pathway is the main intracellular signaling activated by GH. Once JAK2s 
are phosphorylated, they can phosphorylate and activate the STATs (Signal 
transducers and activators of transcription) family of transcription factors 
(Herrington et al., 2000). STATs can in fact bind the phospho-residues on 
either JAK2 or GHR, thus allowing JAK2 molecules to exert their kinasic 
activity. Once phosphorylated STATs can dimerize and translocate into the 
nucleus allowing the transcription of target genes.  
As regard to GH, only one member of the family, STAT5is the responsible for its 
specific signal transduction (Gebert CA et al., 1999). STAT5 mutations in 
humans are indeed linked to severe growth delays. There are STAT5 responsive 
elements in IGF1 promoter too, suggesting that the observed phenotype could 
also be dependent on an impairment inIGF1 production (Woelfle et al., 2003; 
Chia et al., 2006). 
 
2. MAPKs PATHWAY  
The scaffold protein Shc can bind the activated complex GHR-JAK2. This 
binding is necessary for its phosphorylation and recruitment of Grb2 and SOS 
proteins, responsible of Ras activation. Ras can then phosphorylate Raf, which 
activates ERK1 and 2, upstream ELK1, the transcription factors at the end of 
the MAPK cascade (Winston et al., 1992, 1995; Vanderkuur, 1995). 
This pathway can however be activated also in a JAK2 independent manner, 
through the recruitment in membrane of the tyrosine kinase Src, able to bind 
the phospo-tyrosines of GHR, with the involvement of phospholipase D 
signaling, which ends with activation of ERK1-2 (Zhu et al., 2002). 
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3. PI3K/AKT PATHWAY 
The mechanism by which GH activates phosphatidil-inositol-3 kinase (PI3K) is 
the phosphorylation of the insulin receptor substrate, IRS, with consequent 
activation of IGF1 and IGF2 signaling (Costoya et al., 1999). 
 
 
 
 
Fig 1.4.1 Schematic representation of the possible intracellular cascades activated by GH 
 
The switching off of GH pathway is achieved by recruiting the suppressor of 
cytokine signals (SOCS) family. 
Four members are involved in the negative regulation of the JAK/STAT 
pathway: SOCS1, SOCS2, SOCS3, and CIS (Flores-Morales et al., 2006). 
SOCS1 can bind the phospho-tyrosine of JAK2 in the catalytic domain, 
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inhibiting its activity (Yasukawa et al., 1999). SOCS3 can bind to both JAK2 
and the phosphorylated residues on GHR (Hansen et al., 1999), whereas the 
precise mechanism by which SOCS2 regulates GH signaling is still unclear. 
Stronger evidences indicate that SOCS2 may bind both the SHP2-binding sites 
on the GHR and the phospho-tyrosine in the activation loop of JAK2, inhibiting 
JAK2 tyrosine phosphorylation itself and the activation of STAT5. Interestingly, 
SOCS2 actions may not be confined to regulating GH signaling. SOCS2 directly 
binds the IGF1 receptor and therefore it is possible that SOCS2 also regulates 
IGF-1 signaling, although IGF1 does not induce SOCS2 expression (Pass et al.,  
2009).  
Another feature of SOCS proteins is that they are involved in the proteasome 
degradation of GHR due to the intrinsic activity of ubiquitin ligases (Flores-
Morales et al., 2006). The receptor activity can also be blunted by its 
internalization or by the cutting off of the extracellular domain mediated by the 
Tumor necrosis factor α converting enzyme (TACE) (Zhang et al., 2000).  The 
remaining domains are internalized and can translocate into the nucleus 
modulating gene transcription, common behavior with other similar hormones 
like ErbB (Linggi et al., 2006). 
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1.5 ESTROGENS AND 17β-ESTRADIOL  
Estrogens are a group of steroid hormones, whose name derive from the greek 
words “oistros”, the name for women fertility period, and “gen” the suffix of the 
verb to generate. As the semantics indicate, these hormones are known for 
their role in developing the female phenotype.  
There are 3 different biological estrogens: estrone (E1), 17β-estradiol (E2) and 
estriol (E3). In young non-pregnant ladies E2is the most prevalent; E1 is 
produced during menopause; E3 is the pregnancy hormone. In women 
estrogens are produced by the maturating ovarian follicle, by the placenta and 
the corpus luteum, whereas in men they are produced in the testes. Their 
synthesis is stimulated by FSH (follicle stimulating hormone) and LH 
(luteinizing hormone). Traces are also produced by liver, mammary glands, and 
adrenal gland. Estrogens derive from androgens metabolism. The synthesis 
starts by progesterone, which is converted in estrone or estradiol, directly or 
via the conversion of testosterone through the enzyme aromatase. Estrogens 
are important both in men and women. In men they are necessary for certain 
function of the reproductive apparatus and for sperm maturation (Hess et al., 
1997; Raloff et al., 2008) and in women for the development of secondary 
sexual characteristics and the correct function of the menstrual cycle. In 
addition they regulate body fat distribution and favour triglycerides synthesis. 
Estrogens protect blood vessels from atherosclerosis by increasing the amount 
of HDL. Considering that overall women have more estrogens than men until 
menopause, they have fewer risks of cardiovascular diseases. Since estrogens 
are steroidal compounds, they generally diffuse through the lipid bilayer 
membrane and bind to the specific cytoplasmic receptor with the consequent 
activation/repression of gene transcription (Whitehead & Nussey, 2001). 
E2 is the most potent among estrogens and is produced by the gonads, 
adipocytes and cerebral cells. For example the divergent females and males 
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behaviors can be ascribed to the levels of estradiol produced by the central 
nervous system during fetal development (Simerlyet al., 2002). 
In the plasma E2 is usually bound to globulins or albumin, so that only a little 
fraction is free and biologically active. E2 levels are used as markers for follicle 
activity, menstrual dysfunctions, and menopause. High levels of E2often 
correlate with the presence of tumors.  
E2 effects are not only restricted to the female reproductive apparatus. In liver 
it can inhibit IGF1 synthesis, in arteries it favours fluent blood flux (Collins et 
al., 2004), and loss of E2 in bone is linked to osteoporosis an osteopenia 
(Carani et al., 1997). Another major target organ for E2 is the brain, where it 
acts as a neuroprotective compound (Behl et al., 1995) and is involved in both 
pre- and postnatal brain development. 
 
17β-ESTRADIOL AND BONE 
E2 deficiency, caused both by menopause or ovariectomy, is associated with a 
rapid loss in bone mass, especially in the trabecular bone. Cortical bone loss is 
subsequent to the trabecular one and slower (Riggs et al., 2002). Even in males 
the lack of E2 affects bone mass; individuals carrying a deletion of the estrogen 
receptor α  gene suffer from osteopenia and high resorption rate (Smith et al., 
1994), the same phenotype is shared by males lacking the aromatase activity 
(Morishima et al., 1995) 
Clinical studies have shown that E2 plays a role in inhibiting bone resorption. 
E2 inhibits RANKL expression, while increasing OPG (Eghbali-Fatourechi et 
al., 2003). Moreover it induces OCs apoptosis through the Fas pathway (Garcia 
AJ 2013). As regards osteoblasts it favours the maturation (Falahati et al., 
2000) and inhibits the apoptosis (Bradford et al., 2010). It seems to also trigger 
the osteogenic differentiation of mesenchymal precursors. Dang and colleagues 
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showed using both murine primary cells and the cell line KS483, that E2 
increases the osteogenic commitment and inhibits the adipogenic one, when 
cultured in  osteogenic or adipogenic medium, respectively  (Dang et al.,2002). 
The same results were shown using human MSCs (Zhao et al., 2011). However 
it seems that in MSCs not committed to any of the possible lineages, E2 exerts 
more a proliferative effect on the stromal precursors (Hong et al., 2011) 
 
ESTROGENS AND AGING 
The decrease of circulating estradiol during aging is associated to bone loss 
both in male and in female (Riggs BL 1998; Khosla S 1998; Tuck SP 2008).  
In postmenopausal women the increase in the bone marrow adiposity (Syed et 
al., 2008) can be rescued by estrogen replacement therapy (Benayahu et al., 
2000; Somjen et al., 2011). Moreover the anti-aging effects of estrogens include 
the protective effect against OS. Almeida and colleagues showed that estrogens 
have the capability of diminishing OS in bone and bone marrow, attenuating 
the OS induced osteoblasts apoptosis and the impaired osteoblastogenesis 
(Almeida et al., 2009).  
Estrogen deficiency has also been associated with a reduced expression of 
SIRT1 (Elbaz et al., 2009), a NAD-dependent deacetylaserecently defined as a 
key longevity factor(Kim et al., 2012) 
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ESTROGEN SIGNALLING 
E2 exerts its action through the binding to specific receptors, the estrogen 
receptors (ERs), which are mainly present in the cytoplasm. The ligand-
receptor complexes dimerize and translocate into the nucleus where they bind 
to specific DNA palindromic regions called ERE (estrogen responsive elements, 
ERE= GGTCAnnnTGACC). Here they operate with co-activators or co-
repressors of gene transcription (Klinge et al., 2000). They can also regulate the 
transcription of genes whose promoter is lacking the ERE consensus, by direct 
interaction with other transcription factors on the DNA, like AP1 or Sp-1(Safe 
et al., 2001). These complexes can also have a cytoplasmic activity 
independent of the DNA binding (Levin, et al., 2005). 
Some ERs can be associated to the cell membrane and can be activated after 
exposure to the hormone. They are associated with G proteins, Tyrosine kinase 
(TK) receptors (i.e. EGRF, epidermal growth factor receptor) and non-TK 
receptors, like Src (Levin et al., 2005). Through the TK receptors E2 action is 
mediated by the activation of MAPKs and ERK pathway (Kato et al., 1995). E2 
can also bind the GPR30 receptor (Otto et al., 2008), but the precise role of this 
receptor is still under investigation. 
The first ER was cloned in 1986 by Green and colleagues (Green et al.,1986 a; 
Greene et al., 1986 b), and was considered the only onetill 1996. In that year it 
was indeed cloned the second E2 binding protein (Kuiper et al., 1996). The two 
receptors are nowadays known as ERα and ERβ. They have an identity of 97% 
in the amino acidic sequence of the DNA binding domain and only of 56% in 
the ligand binding domain. The genes coding for ERα and ERβ are ESR1 and 
ESR2 respectively. ESR1 is located on chromosome 6 whereas ESR2 on 
chromosome 14. They are present in almost all body tissues and usually in the 
same amount. In specific organs, however, one isoform can be more expressed 
than the other one. ERα is the most abundant in uterus, prostate stromal 
cells, ovaries, testes, breast, liver, white adipose tissue, some brain areas and 
bone. ERβ is mostly expressed in colon, prostate epithelium, vascular 
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endothelium, salivary glands (Karin et al., 2006).  ERs are over-expressed in 
around the 70% of breast cancers and are considered to be the cause of the 
tumor formation. Indeed estrogens stimulate proliferation with an increase in 
DNA replication and a consequent increase in the risk of mutagenesis, and 
produce genotoxic waste through their own metabolism. In both cases the 
results is a misregulation of the cell cycle, of the apoptotic program and of the 
DNA repair. The involvement of ERα in breast cancer has been widely 
demonstrated, whereas the role of ER β is still under investigation. ERβ is 
however linked to the formation of the colon tumor (Harris et al., 2003) 
 
 
Fig 1.5.1 Schematic representation of the possible intracellular cascades activated by 
estrogens modified from Nadal et al 2001  
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1.6 SERMS 
Selective estrogen receptor modulators (SERMs) are non-steroidal compounds 
binding the estrogen receptor.  
SERMs display estrogen receptor agonist properties in some tissues and 
estrogen receptor antagonist in others (Goldstein et al., 2000). The molecular 
mechanisms responsible for the opposite responses to the same SERM are the 
different affinity for the receptor subtype and the diverse recruitment of co-
activators/co-repressors in the cells (Dutertre &Smith 2000). SERMS 
molecules are studied since the 50s, although the very first public description 
of the possible use of SERMs in clinics was in 1987in New York, at the First 
International Chemoprevention meeting (Masimov et al., 2013). Among the 
SERMs molecules, Tamoxifen and Raloxifene, being among the first discovered, 
are the better characterized. They both have anti-estrogenic effect on breast 
and agonist properties on bone.  
 
 
TAMOXIFEN 
Tamoxifen has anti-estrogen activity in the breast and estrogen-like activity in 
the uterus (Fisher et al., 1994). The agonistic properties are driven by elevated 
intracellular levels of steroid receptor co-activator 1 (SRC-1), which are higher 
in the uterus than in the breast (Yatrik &Rowan 2005; Klessler et al., 2007). 
In clinics tamoxifen use has been approved for the treatment of metastatic 
breast cancer, adjuvant therapy alone, for reducing the risks of cancer in high 
risk post-menopausal women, for men breast cancer and for the ductal 
carcinoma in situ treatment (Maximov et al., 2013). Clinical studies have 
highlighted cardio protective effects and bone anabolic properties (Love et al., 
1992; Christodoulakos et al., 2006).  
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RALOXIFENE 
Raloxifene has estrogenic actions on bone and anti-estrogenic actions on 
breast. Since raloxifene recruits mainly co-repressor proteins, it is an estrogen 
antagonist in the uterus, despite the high concentration of co-activators 
(Klesser et al., 2007). In 2006the National Cancer Institute announced that 
raloxifene was comparable to tamoxifen in reducing the incidence of breast 
cancer in postmenopausal women at high risk. One year later, the Food and 
Drug administration declared the raloxifene approval for the prevention and 
reduction of invasive breast cancer risks in postmenopausal women with high 
risks of osteoporosis, and for the treatment of osteoporosis in postmenopausal 
women with high risks of invasive breast cancer(Maximov et al., 2013).  The 
trial for the Multiple Outcomes of Raloxifene Evaluation (MORE) found that 
postmenopausal women suffering from osteoporosis when treated 3 years with 
raloxifene 60 and 120 mg/day showed, compared with placebo, significantly 
reduced vertebral fracture risk by 30% and 50%, respectively (Ettinger et al.,  
1999). As well as tamoxifen, raloxifene induces vasomotor side effects (Stovall 
et al., 2007, Cohen et al., 2000). 
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Most of the therapies for the treatment of osteoporosis are based on the 
inhibition of bone resorption and only few available therapies are anabolic ( i.e. 
able to stimulate bone formation). Blocking the fast bone loss by inhibiting 
bone resorption is crucial for preventing the worsening of the disease. However, 
this therapy is not optimal because the inhibition of the physiological bone 
turnover could affect the bone quality. The blockage of osteoclasts activity 
might not be sufficient to restore a normal BMD. Hence characterizing the 
complex physiology of bone mass maintenance is the base to discover novel 
anabolic drugs for increasing BMD and decreasing bone fragility in the 
treatment of osteoporosis.  
The GH/IGFs pathway is a complex process that regulates key aspects of 
growth and metabolism. GH is responsible of increased height during 
childhood and it is important to maintain bone mass and homeostasis in the 
adult (Giustina et al. 2008). Congenital GH deficiency in humans and animals 
results in decreased bone growth and osteopenia (Ohlsson et al., 1998). 
Estrogens are responsible for the development of secondary sexual 
characteristics, and they play a major role by regulating both somatic growth 
and the preservation of bone mass (Turner et al., 1994). There is a close 
interplay between estrogens and GH. The regulatory activity by E2 on GH may 
occur at many levels, secretion, clearance and action, and in different tissues. 
E2 favours the pituitary secretion of GH and can also influence the general 
responsiveness to GH replacement therapy in GH-deficient adults [Drake WM, 
2001, Rossini A 2011]. In accordance to this evidence, orally administered 
estrogens reduce the metabolic action of GH in liver. In 2003 Leung and 
colleagues demonstrated that, in hepatoma and breast cancer cells, E2 inhibits 
GH-dependent activation of GH intracellular pathway (JAK2/STAT5) by 
increasing the expression of the inhibitor SOCS2 (Leung 2003). Interactions 
between hormones at a cellular level often occur in the organism (Birzniece et 
al., 2009) and post receptor modulations of cellular signaling could have a 
physiological relevance for reciprocal modulation of the activity. 
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In bone little is known about the possible regulation exerted by E2 on GH 
intracellular pathway. In the present study I decided to investigate the local 
interplay between E2 and GH that might occur in bone. For this purpose I 
evaluated the effects of GH and E2 in primary culture of human osteoblasts 
(hOBS) or their precursors, human mesenchymal stromal cells (hMSCs). 
Considering the widespread use of selective estrogen receptor modulators 
(SERMs) in therapy, I investigated if Raloxifene and Tamoxifen could display 
the same features as E2 in hOBs.  
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3.1 DRUGS 
Human recombinant growth hormone (GH), 17-estradiol (E2), actinomycin D, 
MG132, Tamoxifen and Raloxifene were purchased from Sigma (Milan, Italy).  
 
3.2 CELLS CULTURES 
Human osteoblasts (hOBs) cultures 
Human bone cell cultures were established by means of a modified version of 
the Gehron-Robey and Termine procedure (Gehron-Robey&Termine 1985) 
using trabecular bone samples obtained from waste material of female patients 
during orthopaedic surgery for degenerative diseases or traumatic fractures of 
the femoral neck requiring osteotomy. None of the patients (aged 68–81yr) had 
any malignant bone diseases and all of them gave their written consent for the 
use of the waste material. The protocol was approved by the Institutional 
Ethical Committee. No significant trend related to donor age was observed in 
any of the effects studied. Briefly, the trabecular bone was cut into small 
pieces and thoroughly washed with commercial standardized Joklik’s modified 
MEM (Sigma, Milan, Italy) serum-free medium, to remove non adherent 
marrow cells. The pieces were incubated with rotation at 37°C for 30 min with 
the same medium containing 0.5 mg/ml type IV collagenase (Sigma, Milan, 
Italy), and collagenase digestion was stopped by the addition of Iscove’s 
modified medium (IMDM, Lonza, Walkersville, MD, USA) containing 10% foetal 
bovine serum (FBS, Euroclone, Milan, Italy). Between eight and ten pieces from 
each patient were then placed in 25cm2 flasks and cultured in IMDM 
containing 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 U/ml 
mycostatin, and 0.25µg/ml amphotericin B until confluence; the culture 
medium was changed every 2–3 days. At the first passage the culture medium 
was changed to Dulbecco’s modified essential medium (DMEM, Sigma, Milan, 
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Italy) without phenol red with 10% FBS and antibiotics as IMDM. The cell 
population was tested for alkaline phosphatase and osteocalcin production 
after 1,25(OH)2D3 10-8M to ensure that the cells were endowed with osteoblast 
characteristics. Cells were used at first passage to reduce the possibility of 
phenotype changes.  
 
 
Human mesenchymal stromal cells (hMSCs) cultures 
Human mesenchymal stromal cells were isolated from the trabecular bone 
samples as described above for hOBs. The protocol was approved by the 
Institutional Ethical Committee. No significant trend related to donor age was 
observed in any of the effects studied. In accordance with the procedure of 
Zhou and colleagues (Zhou et al., 2008) the samples were washed several times 
with PBS to remove the remaining marrow from the bone. The washing 
solution was centrifuged and the pellet resuspended in 10 ml of PBS. The 
mononucleated cells were isolated on a density gradient centrifugation 
(Histopaque-1.077, Sigma, Milan, Italy). The isolated cells were then plated in a 
25 cm2 flasks. After 24 hours, the medium was replaced with fresh one to 
eliminate the non-adherent cells. Cells used for FACS analysis and 
experiments were at the third/fourth passage as suggested by NIH (Horwitz 
2006). hMSCs were cultivated in 10% FBS low glucose phenol red-free 
Dulbecco’s modified essential medium (DMEM, Sigma, Milan, Italy) with 
antibiotics. For GH and E2 treatments cells were cultivated in DMEM 
supplemented with 1% FBS and 9% charcoal stripped FBS (Sigma, Milan, 
Italy). The GH and E2 concentrations were the same as for OBs.  
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3.3 FACS ANALYSIS 
The expression of specific MSC markers, CD105, CD73, CD90, CD34, CD45 
was evaluated by flow cytometry (FACS). A total amount of 105 harvested cells 
was used for each experimental condition. After washing with PBS-FACS (PBS 
+ 0.1% BSA), the cells were incubated for 20 min with the following 
fluorescence-labeled antibodies diluted 1:200: CD90-APC (BD Pharmingen), 
CD73-PE (BD Pharmingen), CD105-biotinylated (R&D systems, MN, USA) 
CD34-PE-Cy5 (BD Pharmingen, NJ, USA) and CD45-Pacific Blue (BD 
Pharmingen, NJ, USA). Surface staining was followed by PE-Cy7-conjugated 
secondary antibody (BD Pharmingen) staining for the detection of CD105. To 
determine the background fluorescence for each antibody, both unstained 
samples and immunoglobulin-matched isotype samples were included in each 
analysis. 
Samples were acquired immediately with an LSRII FACS (BD Pharmingen) and 
analyzed using FlowJo software 2.2 (TreeStar Inc., OR, USA). Forward scatter-
area versus forward scatter-height properties were used to exclude cell 
aggregates, and live cells were separated from dead cells. The cells were first 
gated for CD90 and then for CD73 and CD105 expression. In the triple positive 
population, the frequency of CD45 and CD34 double positive cells was 
calculated.  
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3.4 DIFFERENTIATION ASSAY 
Differentiation assays were performed on hMSCs challenged for 14 days with 
pro-osteogenic medium (osteoMEM) that consisted of growthMEM 
supplemented with 50 µg/ml 2-phosphoascorbic acid, 10 mM ß-
glycerophosphate, and 10-7 M dexamethasone, or with pro-adipogenic medium 
(adipoMEM) containinggrowthMEM supplemented with 5x10-4 M 3-isobutyl-1-
methylxantin (IBMX), 10-4 M indomethacin, and 10-6 M dexamethasone. The 
controls consisted of cells cultured in growthMEM.  
To assess osteogenic differentiation, cells were fixed in 70% ethanol in sterile 
water for 10 min and stained with Alizarin red S (40 mM, pH 4.1–4.3) for 20 
min to color the mineralized matrix. Images were acquired using an Epson 
Scanner. To assess adipogenic differentiation, cells were fixed in 60% 
isopropanol for 10 min and then stained with Oil Red O (ORO) (0.3% w/v in 
60% isopropanol) for 15 min to color the lipid droplets present in the newly-
formed adipocytes. Images were taken with an inverted microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) at 10X or 20X magnification. The 
accumulation of ORO was quantified after de-staining of the cellular monolayer 
by incubating it in 100% isopropanol for 10 min and measuring the 
absorbance at 500 nm on a plate reader, Infinite 2000 (Tecan Italia s.r.l., 
Milan, Italy). Results were expressed as a ratio of the absorbance to the DNA 
content of each sample. 
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3.5 REAL TIME qPCR 
Real Time PCR for messenger RNAs  
Total RNA from confluent hOBsor hMSCs was extracted using TRIzol according 
to the manufacturer’s instructions (Invitrogen Life Technology, Inc., Paisley, 
UK). RNA pellets were dissolved in sterile distilled water and their 
concentrations were assessed by spectrophotometric analysis (OD260/280). 
One µg of total RNA was retrotranscribed in a total volume of 25µl using an 
oligodT primer (0.5µM), 200 U of M-MLV Reverse Transcriptase, 
deoxynucleotides (0.5mM), M-MLV reaction Buffer 1x and rRNasin 
Ribonuclease Inhibitor 1U/µl (Promega Corporation, Madison, WI, USA). 
The relative expression of osteopontin (OPN), bone sialoprotein (BSP), and IGF2 
mRNA was evaluated in hOBs. At confluence after 24h of serum starvation, 
cells were treated for 6 h with GH (5 ng/ml) or E2 (10-8 M). For the combined 
treatment with the two hormones, E2 was added 60 min before GH. The 
relative expression of SOCS1, SOCS2 and SOCS3 mRNA was evaluated 60 min 
after treatment with E2 (10-8 M)/Tam(10-10 M )/Ral (10-8 M) In human MSCs 
the expression of OPG, OSX, RUNX2, ADN, C/EBP α was evaluated after 14 
days long term treatment with GH (5ng/ml; 3 times/week).   
Relative quantification of mRNA expression was performed on an ABI PRISM 
7900 sequence detector (Applied Biosystems, Foster City, CA, USA) using 10 
ng cDNA of the RT-PCR solution in a final volume of 25µl. The primer-probe 
sets were purchased as Assay-on-Demand for gene expression from Applied 
Biosystems. Real Time PCR was performed with FAM labelled specific probes 
for IGF2, OPN, BSP, SOCS1, SOCS2, SOCS3, OSX, RUNX2, ADN, C/EBPS and 
-actin, which is the housekeeping gene used as endogenous control.  
Real Time PCR was run according to the following protocol: an initial step of 2 
min at 50°C and 10 min at 95°C followed by 40 cycles of 15s at 95°C and 1 
min at 60°C. mRNA levels were quantified using the comparative threshold-
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cycle (Ct) method. First, the amount of target mRNA in each sample was 
normalized to the amount of the housekeeper mRNA (-actin), designated as a 
calibrator, to give ΔCt (Cttarget - Ct-actin). Second, the amounts of target mRNA in 
the samples were expressed using the formula: Amount of target mRNA = 2-ΔΔCt, 
where ΔΔCt = ΔCt (sample1) - ΔCt (untreated sample). Three replicates were performed for 
each experimental point and experiments were repeated several times with 
cells obtained from different donors.  
 
Real Time PCR for microRNAs  
In human MSCs the expression of miR-22, miR-29c and miR-204 was 
evaluated after 14 days of GH or E2 (5ng/ml, 10-8M respectively; 3 
times/week); for the combined treatment cells were pretreated 60’ with E2 
before GH. For each RT reaction, in accordance with the manufacturer’s 
protocol (TaqMan® Small RNA Assays, Applied Biosystems), 10 ng of RNA were 
combined with a RT master mix containing 1mM dNTPs, MultiScribe™ Reverse 
Transcriptase 50 U, 1X Reverse Transcription Buffer, RNase Inhibitor 3,8 U 
and 1X of the kit-included specific primers. The reaction was performed for 30 
min at 16°C, thenfor 30 min at 42°C, with a final 5’ step at 85°C. From this 
reaction 1.33 µl were used for the Real Time PCR amplification. The cDNA was 
mixed with 1x TaqMan® Small RNA Assay and 1X TaqMan® Universal PCR 
Master Mix II. The PCR reaction was performed following the same protocol 
used for the mRNAs.  
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3.6 WESTERN BLOT ANALYSIS 
Phosphorylated-STAT5 (P-STAT5) and STAT5 protein levels were tested in 
confluent hOBs or hMSCs after 24h of serum starvation and treated for 60 min 
with different doses of GH (0.1ng/ml-20ng/ml), or E2 (10-8M), or Tam(10-10 M), 
Ral (10-8 M) or E2/Ral/Tam with GH (5ng/ml). In this latter case the treatment 
was added 60 min before GH. SOCS1, SOCS2 and SOCS3 protein levels were 
detected in 24h serum starved hOBs after 60 min treatment with E2 (10-8 M) 
Tam(10-10 M )/Ral (10-8 M). Actinomycin D (5µM) was added 30 min before E2.  
After removing the medium, adherent cells were gently scraped into 75µl lysis 
buffer (Hepes 50mM, NaCl 250mM, MgCl2 5mM, 1% Triton, 10% Glycerol, 
protease and phosphatase inhibitors cocktail (1:100, Sigma, Milan, Italy). The 
lysates were centrifuged at 12,000 rpm for 10 min at 4°C and the supernatants 
were collected and the total protein concentration was determined by BCA 
assay (Pierce, Rockford, IL, USA). Thirty-five micrograms of total protein extract 
were mixed with the appropriate volume of Laemmli’s sample loading buffer, 
heated at 100°C for 5 min and loaded onto 10% SDS polyacrylamide gels. 
Western blots were performed using specific antibodies against human P-
STAT5, STAT5, SOCS2, SOCS1 and SOCS3 (Cell Signalling Technology, 
Boston, MA, USA) diluted 1:200, 1:1000, 1:500 and 1:1000, respectively, in 5% 
milk or BSA Tris Buffered Saline with 0.1% Tween20. After rinsing, membrane 
was treated with specific horseradish peroxidase conjugated secondary 
antibodies (1:2000) and enhanced chemiluminescence substrate (ECL, Pierce). 
Bands on x-ray films were then quantified using Scion Image software (Scion 
Corp., Frederick, MD, USA). β-actin was used as an endogenous control to 
avoid incorrect estimations of the signal of the protein tested. The intensity of 
the treated samples were normalized to that of the untreated samples (untr).  
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3.7 CO-IMMUNOPRECIPITATION 
For the immunoprecipitation assays hOBs were treated 60 min with E2 (10-8M) 
and lysed in RIPA Buffer added with protease and phosphatase inhibitor 
cocktail (Sigma, Milan, Italy). Five hundred micrograms of these total protein 
extracts were incubated for 2h at 4°C with 2μg of anti-ubiquitin primary 
antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany). Then 20 μl of 
Protein A-agarose (Santa Cruz Biotechnology Inc., Heidelberg, Germany) were 
added and samples incubated on a rotating device overnight at 4ºC. The so 
formed sepharose bound immune complexes were collected by centrifugation 
at 4°C for 5 min at 3500 rpm. Pellets were washed 4 times with 1ml of PBS, 
each time repeating centrifugation step with the following conditions: 6 min at 
3500 rpm; twice 6 min at 3000 rpm, 7 min at 3500 rpm. After the final wash 
pellets were resuspended in 40 μl of Laemmli sample buffer denaturating 1x 
and boiled for 3 min. Twenty microliters of each sample were used to perform a 
SDS-PAGE assay, followed by immunoblot analysis. The blots were quantified 
by Scion Image software as described for western blots. 
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3.8 siRNA-MEDIATED SOCS2 GENE SILENCING 
Subconfluent (80%) hOBs were transfected with a pool of predesigned short 
interfering RNAs (FlexiTube GeneSolution for SOCS2, Qiagen, Milan, Italy) 
targeting human SOCS2 and a control scrambled RNA (AllStars Negative 
Control, Qiagen, Milan, Italy), targeting a sequence not sharing homology with 
the human genome using the RNAiFect transfection reagent (Qiagen, Milan, 
Italy) according to the manufaturer’s instructions. hOBs were incubated with 
the transfection complexes for 48 hrs at 37°C and 5% CO2 before treatment. A 
ratio of 1µg siRNA: 3µl RNAifect was used as it provided an average gene 
silencing of 75% as determined by real time PCR (Fig.4:8A).  
 
3.9 STATISTICAL ANALYSIS 
Statistical analysis was performed by means of the statistical package Prism vs 
4.00, (GraphPad Software, San Diego, CA, USA). Statistically significant 
differences were determined using the nonparametric ANOVA test (Kruskal-
Wallis test) followed by multiple-comparison test (Dunn’s post-test) or by the 
Mann-Whitney test. 
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4.1 STAT5 phosphorylation induced by GH and E2 in   
hOBs 
Since JAK2/STAT5 cascade is the major pathway activated by GH, I first 
evaluated the concentration of GH and the time-course required to induce the 
activation of this pathway in hOBs. Different concentrations of GH (0.1, 1, 5, 
10, and 20 ng/ml) induced a concentration-dependent increase in the 
phosphorylation of STAT5 (P-STAT5) after 60 min exposure. The increase in P-
STAT5 was statistically significant from 5ng/ml (P< 0.05) to 20ng/ml (P< 0.01) 
(Fig. 4.1 A). GH treatment (5ng/ml) induced a time-dependent increase in P-
STAT5 that became significant from 30 min until 90 min (Fig. 1B). Considering 
these results, I chose the following experimental conditions for the assessment 
of STAT5 phosphorylation: a GH concentration of 5ng/ml and  60 min 
treatment. 
I then analysed E2 possible modulation of GH intracellular pathway. E2 pre-
treatment (10-8 M) 60 min before GH induced a significant increase (P<0.01) of 
P-STAT5 compared with GH alone, E2 (10-8M) per se had no effect on P-STAT 
levels. In hOBs treated with the two hormones at the same time, E2 did not 
increase GH dependent STAT5 phosphorylation (Fig. 4.2). The total amount of 
STAT5 did not change after exposure to either GH (5 ng/ml) or E2 (10-8M) (Fig. 
4.1-2). On the basis of these results cells were always pre-treated with E2 60 
min before GH. 
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Fig. 4.1.A: STAT5 phosphorylation (P-STAT5) in responseto increasing concentrations of 
GH (0.1-20 ng/ml) after 60 min treatment in hOBs ; representative Western blots and 
relevant quantification, as described in the Materials and Methods (n = 6). No changes in 
the total amounts of STAT5 were observed B: Time-course of 5 ng/ml GH treatment on P-
STAT5 (n = 3); ** P < 0.01, * P < 0.05 vs. untreated cells (untr); Kruskal-Wallis with 
Dunn’s test for multiple comparisons. 
 
 
Fig.4.2. The effect of 60 min GH 
(5ng/ml) or E2 (10-8M) treatment on 
STAT5 phosphorylation (P-STAT5). 
For the combined treatment with the 
two hormones, E2 was added at the 
same time as GH (black bar) or 60 
min before (squared bar). No changes 
in total amount of  STAT5 were 
detected. Representative Western blots and relevant quantification, as described in 
Materials and Methods, (n = 9); ** P < 0.01 vs. untreated cells (untr), § P < 0.05 vs. GH; 
Kruskal-Wallis with Dunn’s test for multiple comparisons. 
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4.2 Effect of E2 on GH-related gene expression 
 As P-STAT5 activates the transcription of GH-related genes, the mRNA 
expression of OPN, BSP, and IGF2 was measured 6 h after GH (5 ng/ml) or E2 
(10-8 M). GH induced significant increases in OPN (P< 0.01), BSP (P< 0.05), and 
IGF2 (P< 0.05) mRNAs. E2 (10-8 M)  pre-treatment 60 min before GH further 
increased the effect of GH on OPN, BSP, and IGF2 expression (Fig. 4.3), 
indicating that E2 exerts a positive modulatory action on GH-induced gene 
expression in hOBs. 
 
 
 
 
 
 
 
 
Fig. 4.3. Osteopontin (OPN), bone sialoprotein (BSP), and IGF2 mRNA expression 
measured 6 h after GH (5 ng/ml) or E2 (10-8M) treatment in hOBs. In the combined 
treatment with the two hormones, hOBs were pre-treated with E2 60 min before GH (n = 
6). ** P < 0.01, * P < 0.05 vs. untreated cells (untr), § P < 0.05 vs. E2 and vs. GH; 
Kruskal-Wallis with Dunn’s test for multiple comparisons. 
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4.3 Effects of E2 on SOCS proteins at 1 h 
Considering the role of SOCS proteins as feedback inhibitors of GH signalling, I 
evaluated the effects of E2 on GH pathway inhibitors, SOCS1, SOCS2, and 
SOCS3. I analysed both mRNAs and protein levels. Treatment for 60 min with 
E2 (10-8 M) did not modify neither protein levels nor mRNA of SOCS1 and 
SOCS3 in hOBs (Fig.4.4 A&B), while E2 significantly reduced SOCS2 protein 
level (Fig. 4.4A) without affecting its mRNA level (Fig.4.4B).  
 
Fig. 4.4A: SOCS1, 2, 
3 protein levels 
measured after 60 
min E2 (10-8M) 
treatment 
(representative 
Western blots and 
relevant 
quantifications; n = 3).  
B: SOCS1, 2, 3 mRNA 
expression after 60 
min E2 (10-8M) 
treatment in hOBs (n = 
6). *** P < 0.001, ** 
P<0.01 vs. untreated 
cells (untr); Kruskal-
Wallis with Dunn’s 
test for multiple 
comparisons. 
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E2-induced decrease in SOCS2 protein was concentration dependent, being 
statistically significant from 10-10M (P<0.05) to 10-7M (P<0.001) (Fig. 4.5A) and 
time-dependent, becoming significant after 30 min (P<0.05) of treatment and 
lasting until 90 min (P<0.001) (Fig. 4.5 B).  
 
 
 
 
 
 
 
 
Fig. 4.5 A: Dose-dependent decrease of SOCS2 protein levels after 60 min treatment 
with different concentrations of E2 (10-11M-10-7M) (representative Western blots and 
relevant quantification, as described in the Materials and Methods; n = 4). B: Time-
dependent effect of 10-8M E2 treatment on SOCS2 protein levels (n=3). *** P < 0.001, ** 
P<0.01, * P<0.05 vs. untreated cells (untr); Kruskal-Wallis with Dunn’s test for multiple 
comparisons 
 
In human skin fibroblasts E2 10-8M was not able to induce any effect on 
SOCS2 protein levels (Fig. 4.6), suggesting that E2-induced SOCS2 protein 
decrease is cell-specific. 
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Fig. 4.6:The effect of 60 min 10-8M E2 
treatment on SOCS2 protein levels in skin 
derived fibroblasts (representative Western 
blots and relevant quantification, as 
described in the Materials and Methods; n = 
3). E2 does not modify SOCS2 protein levels 
in these cells. 
 
In hOBs neither 60 min treatment with GH (5ng/ml) or E2 (10-8M) nor the 
combined treatment with the two hormones induced any modification of 
SOCS2 mRNA (Fig. 4.7A), whereas E2 pre-treatment 60 min before GH was 
able to induce a significant reduction of SOCS2 protein levels (fig. 4.7B).  
 
 
 
 
 
 
Fig. 4.7 : The effect of 60 min GH (5ng/ml)  
or E2 (10-8M) treatment on SOCS2 mRNA expression (A, n=4) or protein levels (B, n=3) in 
hOBs measured by Western blot and relevant quantification. For the combined treatment 
with the two hormones, E2 was added 60 min before GH. ** P<0.01, *p<0.05 vs 
untreated cells (untr); §§§ P<0.001 vs GH; Kruskal-Wallis with Dunn’s test for multiple 
comparisons.
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In order to evaluate the involvement of SOCS2 in E2 positive modulation of GH 
signalling, hOBs were transfected with small interference RNA (siRNA) 
targeting SOCS2. The reduction in SOCS2 mRNA and protein level obtained in 
transfected hOBs is shown in Fig. 4.8A and B, respectively. 
 
 
 
 
 
 
 
 
Fig. 4.8. The effect of the transfection with the siRNA targeting SOCS2 gene expression 
or scrambled control (siRNA-) of primary hOBs on A: SOCS2 mRNA expression assessed 
by real time PCR to confirm gene knockdown (n=3) and B: SOCS2 protein levels 
measured by Western blot and relevant quantification (n=3). **P<0.01, * P<0.05 vs. 
siRNA-; Mann-Whitney test. 
In cells lacking the negative feedback of SOCS2 on GH signalling, GH induced 
a greater amount of P-STAT5. Sixty min E2 pre-treatment of hOBs silenced for 
SOCS2 was not able to induce any potentiating effect on GH induced STAT5 
phosphorylation (Fig.9A). In hOBs treated with the non-coding siRNA negative 
control, E2 potentiating effect on GH induced P-STAT5 was preserved (Fig. 9A). 
In SOCS2 silenced hOBs, the positive effect of E2 pre-treatment on BSP and 
OPN mRNA expression induced by GH was no longer present (Fig.4.9B). 
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Fig. 4.9 A: The effect of 60 min E2 (10-8M) pre-treatment on GH (5ng/ml) induced STAT5 
phosphorylation (P-STAT5) in hOBs transfected with siRNA targeting SOCS2 gene 
expression (ctrl = siRNA SOCS2, hatched bars, n= 4) or with siRNA non coding control 
(siRNA-) (ctrl = non coding siRNA; white bar, n= 4); B: 60 min E2 pre-treatment effect on 
GH induced BSP and OPN mRNA expression in silenced cells (n= 4). **P<0.01, * P<0.05 
vs siRNA- (ctrl), § P<0.05 vs. GH;  P<0.001 vs ctrl; Kruskal-Wallis with Dunn’s test for 
multiple comparisons 
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In order to assess whether E2 potentiating effect on GH signalling requires de 
novo gene transcription, hOBs were pre-incubated for 30 min with actinomycin 
D before E2 treatment for 60 min. E2 was able to reduce significantly SOCS2 
protein levels also in presence of the inhibitor of transcription, suggesting that 
this E2 effect is non-genomic (Fig. 4.10). 
 
 
 
 
 
 
 
Fig. 4.10: The effect of 30 min actinomycin D (act D, 5µg/ml) pre-treatment before E2 
treatment for 60 min on SOCS2 protein levels in hOBs (representative Western blot and 
relevant quantification; n = 6). ** P<0.01 vs untreated cells (untr),  P <0.01 vs 
actinomycin D; Mann-Whitney test. 
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4.4 Effect of E2 on SOCS2 degradation 
On the basis of these results I investigated whether E2 was able to facilitate 
SOCS2 degradation by evaluating the effect of E2 on SOCS2 ubiquitination. 
Sixty min E2 (10-8 M) treatment was able to significantly increase the amount 
of ubiquitinated SOCS2 protein (Fig. 4.11A). In parallel, non-ubiquitinated 
SOCS2 protein amount measured in the cell lysates after the 
immunoprecipitation of the ubiquitinated proteins was significantly reduced by 
E2 treatment (Fig.4.11B). Pre-treatment with the proteasome inhibitor MG132 
(5 µM) 20 min before E2 prevented the E2-induced reduction in SOCS2 protein 
(Fig. 4.12). These results suggest that E2 amplifies intracellular GH signalling 
by favouring SOCS2 degradation through the proteasome machinery. 
 
 
 
 
 
Fig. 4.11. A: The effect of 60 min E2 (10-8 M) 
treatment on SOCS2 ubiquitination in hOBs 
(representative Western blot following 
immunoprecipitation with ananti-ubiquitin antibody 
and relevant quantification; IgG = negative control;  
n=6). Multiple bands indicate poly-ubiquitination of SOCS2. E2 treatment induced an 
increase in the total ubiquitinated SOCS2 levels. B: Non ubiquitinated SOCS2 protein 
measured in the cell lysate after immunoprecipitation of the ubiquitinated proteins as 
indicated above are decreased after E2 treatment (representative Western blot and 
relevant quantification, n = 6) . ** P < 0.01, * P < 0.05 vs. untreated cells (untr); Mann-
Whitney test. 
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Fig. 4.12. The effect of 20 min pre-treatment with the proteasome inhibitor MG132 (5 
µM) in hOBs on the reduction of SOCS2 protein induced by 60 min E2 (10-8M) treatment 
(n=7). MG132 prevents the inhibitory action of E2 on SOCS2 protein levels. 
(Representative Western blot and relevant quantification). * P < 0.05 vs. untreated cells 
(untr);  P < 0.01 vs. E2 alone; Kruskal-Wallis with Dunn’s test for multiple comparisons. 
 
Fig. 4.12 
 Results 
 
 
 
64 
 
  
4.5 Long term effect of  E2 treatment on STAT5 
phosphorylation and SOCS2 levels 
Having identified a positive role of 60 min E2 pre-treatment on GH pathway, I 
decided to evaluate if the observed effect is maintained over time. For this 
purpose we treated hOBs for 3h with E2 before giving GH. After 3h of E2 pre-
treatment there was still a significant enhancing effect on STAT5 
phosphorylation measured after 60 min of GH treatment (P <0.05) compared to 
GH alone (Fig. 4.13) 
 
 
 
 
 
 
 
 
 
Fig. 4.13 The effect of 60 min GH (5ng/ml) or E2 (10-8M) treatments on STAT5 
phosphorylation (P-STAT5) in hOBs. For the combined treatment with the two hormones 
(squared bar), E2 was added 3h before. No changes in total amount of STAT5 were 
detected. Representative Western blots and relevant quantification, as described in 
Materials and Methods, (n =3); ** P < 0.01 vs. untreated cells (untr), § P < 0.05 vs. GH; 
Kruskal-Wallis with Dunn’s test for multiple comparisons. 
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After 3h E2 (10-8M) pre-treatment, there was a reduction in SOCS2 protein 
levels (Fig 4.14 A), but differently to 60 min E2 pre-treatment, this time there 
was a corresponding decrease in SOCS2 gene expression (Fig. 4.14 B). 
 
 
 
 
 
 
 
 
 
Fig. 4.14A: SOCS2 protein levels measured after 3h  E2 (10-8 M) treatment 
(representative Western blots and relevant quantifications; n = 3). B: SOCS2 mRNA 
expression after 60 min E2 (10-8 M) treatment in hOBs (n = 3). *** P < 0.001, ** P<0.01 vs. 
untreated cells (untr); Kruskal-Wallis with Dunn’s test for multiple comparisons. 
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Moreover cell treated for 3h with E2 in the presence of actinomycin D showed 
no differences in SOCS2 protein levels compared to the relevant control, thus 
suggesting an involvement of a genomic mechanism (Fig. 4.15). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.15: The effect of 30 min actinomycin D (act D, 5µg/ml) pre-treatment before E2 
treatment for 3h on SOCS2 protein levels in hOBs (representative Western blot and 
relevant quantification; n = 6). ** P<0.01 vs untreated cells (untr,; Mann-Whitney test. 
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4.6 Effect of Raloxifene and Tamoxifen pre-
treatments on GH-induced STAT5-
phosphorylation and on SOCS2 levels 
At this point of the research, considering that Selective Estrogen Receptor 
Modulator (SERMS), are endowed of estrogen agonist activity in bone and 
antagonist activity in other tissues, I evaluated if they behave like E2 on GH 
pathway in hOBs.  
Cells were stimulated 60 min with Raloxifene (Ral, 10-8M) or Tamoxifen (Tam, 
10-10M) before giving GH and the level of PSTAT5 was evaluated. Sixty min pre-
treatment with Ral or Tam did not induce a significant increase of P-STAT5 
compared with GH alone (Fig 4.16 A& B); Both SERMS per se had no effect on 
P-STAT5 levels. Total STAT5 levels were not affected by Ral or Tam treatment 
(Fig. 4.16C). I then investigated the effect of both Ral and Tam on SOCS2 gene 
transcription after 3h. None of the two treatments inhibited SOCS2 gene 
expression (Fig 4.17), suggesting that these two SERMs do not share these E2 
activities in bone cells. 
 
Fig. 4.16 A The effect of 60 min GH 
(5ng/ml), Ral (10-8M), or Tam (10-10M) 
treatment on STAT5 phosphorylation (P-
STAT5). For the combined treatment with 
Ral/Tam and GH, SERMS were added 60 
min before. Representative Western blots 
and relevant quantification,as described in 
Materials and Methods, (n =3); *** P < 0.01 
vs. untreated cells (untr), Kruskal-Wallis 
with Dunn’s test for multiple comparisons.  
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B No changes in the total amount of STAT5 were detected; representative Western blots 
and relevant quantification, as described in Materials and Methods, (n =3) 
 
 
Fig 4.17 SOCS 2 mRNA expression 
after 3h Ral (10-8 M) or Tam (10-10M) 
treatment in hOBs (n = 6). Effect not 
significant vs. untreated cells (untr); 
Kruskal-Wallis with Dunn’s test for 
multiple comparisons.  
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4.7 Characterization of human stromal mesenchymal 
stem cells (hMSCs) derived from trabecular bone 
specimens and evaluation of their differentiation 
capability 
Besides mature osteoblasts also their mesenchymal precursors are important 
for the maintenance of bone mass. Therefore I decided to evaluate GH and E2 
interaction in human mesenchymal stem cells. For this purpose hMSCs were 
isolated from trabecular bone according to Zhou et al, 2008 protocol (see 
Material and Methods). I performed a FACS analysis in order to assess the 
presence of CD90, CD73 and CD105, and the lack of CD34 and CD45.  
An average of 75.5% of the cells isolated stained positive for CD90 and around 
64% were simultaneously positive for CD73 and CD105.  Overall 46% of the 
alive population stained positive for all the three CDs. In this triple positive 
population I did not find CD34+ and CD45+ cells (average less than 0.1%), 
which identify hematopoietic precursor cells (Fig. 4.18 A&B). 
After isolation and FACS analysis, cells were tested for their differentiation 
capability by cultivating them in osteogenic or adipogenic medium for 14 days. 
In both the conditions cells were able to differentiate into the osteogenic or 
adipogenic lineage as shown respectively by Alizarin Red and Oil red O 
stainings, thus confirming the pluripotency potential of these cells (Fig 4.19 A& 
B). 
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Fig.4.18  A Representative FACS analysis of 4 different samples of hMSCs stained For 
CD90, CD105 and CD73 compared with a stained compensation control.   
B percentages of the total living cells triple positive. 
Sample % CD90+ → % CD73+CD105+     % + tot live  → CD34+CD45+ 
411_3 97.5  51.6 50.4  0,14 
411_4 96.5  43.4 41.9  0,2 
412 65.4  80.6 52.7  0,01 
417 56  57.4 32.2  0 
419 62   85.1 52.7   0 
Fig. 4.18 
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Fig. 4.19 A Alizarin red staining ofhMSCs cultured 14 days in osteogenic medium (right 
panel) or in normal growth medium (left panel), 6 well plate  B Oil Red O staining of 
hMSCs cultured 14 days in adipogenic medium (right panel) or in normal growth medium 
(left panel), 20x magnification 
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4.8 Effects of E2 on GH intracellular signaling in hMSC 
I then analysed E2-GH post-receptor interaction in hMSCs by applying the 
same experimental schedules of the hOBs experiments. Sixty min E2 (10-8M) 
pre-treatment induced a significant increase (P<0.01) of P-STAT5 compared 
with GH alone whereas E2 (10-8M) per se had no effect on P-STAT5 levels (Fig. 
4.20). Moreover 60 min E2 treatment decreased the protein levels of SOCS2, 
(Fig. 4.21) indicating that E2 enhances GH signalling at post-receptor level, as 
it was observed in hOBs.  
 
Fig. 4.20:  The effect of 60 min GH 
(5ng/ml) or E2 (10-8M) treatment on 
STAT5 phosphorylation (P-STAT5)  in 
hMSCs. For the combined treatment 
with the two hormones, E2 was 
added 60 min before GH. 
 No changes in the  total amount of STAT5 were detected (data not shown).  
Representative Western blots and relevant quantification. ** P < 0.01 vs. untreated cells 
(untr), • P < 0.05 vs. GH; Kruskal-Wallis with Dunn’s test for multiple comparisons. 
 
 
 
Fig. 4.21:The effect of 60 min 10-8M E2 
treatment on SOCS2 protein levels in 
hMSCs, C= untreated cells. Representative 
Western blot and relevant quantification 
(n=3);** P<0.01vs untr; Mann-Whitney test 
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4.9 Validation of the  hMSC model after GH long term 
treatment 
I used hMSCs isolated from trabecular bone to verify the effect of the long term 
treatment of GH (5ng/ml; 3 times/week for14 days) on gene expression. GH 
was able to shift hMSCs towards osteogenesis, as shown by the real-time PCR 
results. GH significantly increased the transcription of OPG and OSX, 
confirming a pro-osteogenic effect of GH on hMSCs. There was a trend to 
increase RUNX2 that did not reach statistical significance whereas ADN and 
C/EBPα were not affected (Fig. 4.22 A&B). 
 
 
 
 
 
 
 
Fig. 4.22.AOsteoprotegerin (OPG) and Osterix (OSX) mRNA expression measured 14 
days after chronic GH treatment of hMSCs (5 ng/ml,3 times/week) cultivated in growth 
medium. * P < 0.05 vs. untreated cells (C); Kruskal-Wallis with Dunn’s test for multiple 
comparisons. B Adiponectin (ADN) and C/EBPα mRNA expression measured in the same 
conditions. 
To further characterize GH role in hMSC differentiation, I treated the cells with 
GH cultivated in a medium favouring adipogenesis (adipoMEM) for 14 days. 
GH was able to drastically reduce adipocytes formation as shown by Oil Red O 
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staining (Fig. 4.23 A). This observation was confirmed by the relative 
quantification of the staining (Fig 4.23B). Concomitantly GH treatment 
decreased significantly the expression of adiponectin (ADN) and C/EBPα (Fig. 
4.23 C) confirming antiadipogenic effect of GH in these types of cells. 
 
 
 
 
 
 
 
 
 
 
 
Fig.23 A Oil Red O staining of hMSCs cultured 14 days in normal growth medium (left 
panel), adipogenic medium (central panel), adipogenic medium with GH (5ng/ml, 3 
times/week, right panel), 10x magnification. BOil Red O staining quantification. Data are 
expressed as a ratio to the DNA amount of the                                                                                                  
relevant sample. ** P < 0.01 vs. untreated cells (untr), • P < 0.05 vs. adipoMEM; Kruskal-
Wallis with Dunn’s test for multiple comparisons. C Adiponectin (ADN) and C/EBPα 
mRNA expression measured 14 days after chronic GH treatment of hMSCs (5 ng/m, 3 
times/week) in adipoMEM;  ** P < 0.01 vs adipoMEM cells; Mann-Whitney test.  
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4.10 Effects of long term GH treatment on miRNA 
expression in hMSCs 
Considering the relevance of microRNAs in MSC differentiation, we evaluated 
the possible changes in the expression of miR-29c, mirR-22, which are known 
to favour osteogenesis and miR-204 which promotes adipogenesis, after GH 
chronic treatment. For this purpose, hMSC cultured in normal growthMEM 
were treated 3times/week with GH (5ng/ml) for 14 days. Accordingly to its pro-
osteogenic activity, GH increased the expressions of miR-22 (P<0.01) and miR-
29c (P<0.05) in hMSC cultured in growthMEM and it had no effect on miR-204 
(Fig. 4.24). 
 
 
 
 
 
 
 
Fig. 24: miR-22 (left panel), miR-29c (central panel)  and miR-204(right panel) expression 
measured 14 days after chronic GH treatment of hMSCs ( 5ng/ml,3 times/week) in 
normal growth medium.* P < 0.05; **P<0,01 vs untreated (untr) cells.   Mann-Whitney 
test. 
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4.11 Effects of the combined treatment of E2 and GH on 
microRNAs in hMSCs. 
Next I investigated the possible interaction E2-GH on the expression of the 
previously evaluated miRNAs in hMSC. Cells were treated with E2 (10-8M) or 
GH (5 ng/ml) for 14 days 3 times/week. In the combined treatment with the 
two hormones, E2 was always given 60 min before GH. E2 treatment per se 
inhibited the expression of all the microRNAs analyzed, miR-22, miR-29c and 
miR-204. E2 pre-treatment was able to inhibit the stimulatory effect of GH on 
miR-22 and miR-29c. E2 decreased miR-204 was maintained also in the 
presence of GH (Fig. 4.25). These results suggest that E2 negative effect on 
miRNA expression per se covers the positive modulation of GH-induced STAT5 
phosphorylation. 
 
 
 
 
 
Fig. 25:  miR-22 ( upper left panel) miR-29c 
(upper right panel) and miR-204 (lower 
panel) expressions measured 14 days after 
GH (5ng/ml), E2 (10-8M), E2+GH treatments 
(3 times/week) in normal growth medium. In 
the combined treatment E2 was given 60 
min before GH;* P < 0.05, ** P <0.01  vs 
untreated  cells; •P<0.05; •• P < 0.01 vs. GH.
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The present study showed for the first time a positive modulation of GH 
intracellular pathway, evaluated as increase in STAT5 phosphorylation, by E2 
pre-treatment, both in hOBs and hMSCs. 
 
5.1 GROWTH HORMONE AND 17β-ESTRADIOL IN hOBs 
In human osteoblasts GH activated the JAK2/STAT5 cascade as in other cells 
types (Leung et al., 2003, Leong et al., 2004). GH concentrations, within the 
physiological range, elicited a significant and dose-dependent phosphorylation 
of STAT5, which in turn activated the transcription of the GH-responsive genes 
IGF2, OPN and BSP. 
In vitro human osteoblasts, in response to GH, do not produce IGF1, but IGF2 
(Mrak  et al 2007). Although IGF1 and IGF2 share the same anabolic features, 
(Froesch et al., 1976), there is increasing evidence that IGF2 plays a critical 
role in the maintenance of bone homeostasis favouring both osteogenic 
differentiation (Hamidouche Z, 2010) and osteoclastogenesis (Fukuoka H, 
2005; Nakao K, 2009). IGF2 production by osteoblasts could modulate the 
bone microenvironment through an autocrine/paracrine mechanism in order 
to create the right conditions for the osteoblasts-osteoclasts coupling and 
therefore for a balanced bone turnover. OPN and BSP are proteins secreted by 
mature osteoblasts involved in matrix deposition and mineralization. Their role 
is not related exclusively to the regulation of mineral turnover; they cooperate 
also to the modulation of bone homeostasis. Global null mice for OPN show 
indeed an altered osteoclastogenesis (Franzén  et al.,  2008) and an 
impairment in MSCs osteogenic/adipogenic commitment (Chen et al, 2013); 
mice KO for BSP display impaired osteoblast and osteoclast function as well 
(Wade-Gueye NM, 2010). Nevertheless, the molecular mechanisms by which 
OPN and BSP control cells metabolism and differentiation have not been yet 
elucidated. E2 through the enhancement of the GH induced production of 
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IGF2, OPN, BSP could further promote the maintenance of the physiological 
homeostasis of bone.  
A previous work of Leung and colleagues (2003) demonstrated that E2 reduces 
GH induced STAT5 phosphorylation in hepatoma and breast cancer cells. The 
opposite effects observed by Leung study and my data could be ascribed to the 
different cell types used: primary human bone cells in this study, instead of 
transfected tumor cell lines as used by Leung’s group. The different cells used 
may also explain the different GH concentrations used for inducing STAT5 
phosphorylation: GH 500ng/ml for cancer cells versus GH 5ng/ml for 
primaries. Investigating hormonal interaction in non-transformed cells in vitro 
gives the advantage to work in conditions closer to a physiological situation, 
thus the concentration used in this study are within the in vivo normal range 
of GH in humans (Hartman et al., 1991) whereas Leung used a dosage 100 
times the physiological hormone levels.  
The mechanism by which E2 positively modulates GH is driven by decreasing 
the amounts of one of its feed-back inhibitor, SOCS2. Three SOCSs are 
generally involved in inhibiting JAK/STAT signaling), SOCS1, SOCS2 and 
SOCS3 (Ahmed SF 2010. All three proteins are expressed in hOBs but only 
SOCS2 in inhibited by E2. The lack of effect on SOCS1 was almost expected 
considering that SOCS1 was shown to act primarily in the immune system 
(Starr R, 1998), whereas the lack of effect of E2 on SOCS3 protein is in 
agreement with previous data obtained in a kidney cell line (Leung KC, 2003). 
Of the three proteins, SOCS2 is of primary importance in skeletal regulation. 
Mice KO for SOCS2 display an altered bone phenotype; the mice grow more 
rapidly, have increased bone growth and longer bone length compared to their 
wild-type littermates [McRae VE 2009]. They exhibit phenotypic characteristics 
of both GH and IGF-I transgenic mice [Metcalf D 2000]. Interestingly, SOCS2 
overexpression enhances growth. It has therefore been proposed that SOCS2 
may exert a dual effect on GH signaling: normal physiological levels of SOCS2 
attenuate the pathway, while higher concentrations of SOCS2 might enhance it 
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by interfering with the activity of other more potent inhibitors (Greenhalgh CJ, 
2002; Pass C, 2009).  
In hOBs the direct involvement of SOCS2 in E2 induced enhancement of 
STAT5 phosphorylation was demonstrated by its specific gene silencing. The 
molecular mechanisms that mediate E2-induced SOCS2 reduction are different 
depending on the timing of the pretreatment. After 1h E2 stimulus there is no 
effect on SOCS2 transcription and the reduction in the protein levels is to be 
ascribed to a non-genomic dependent mechanism. In fact Actinomycin D, that 
inhibits DNA transcription, did not blunt E2 positive effect on STAT5 
phosphorylation. I therefore investigated possible post transcriptional 
regulation mechanism. I focused on the proteasome degradation of the protein, 
discovering that E2 stimulates SOCS2 ubiquitination thus favouring its 
subsequent proteasomal degradation. Indeed pretreatment of cells with the 
proteasome inhibitor MG132, a cell-permeating molecule that specifically 
blocks the activity of the 26S proteasome subunit, prevented E2 induced 
reduction in SOCS2. The ability of E2 to modulate protein stability has been 
recently shown in different cell models and in different direction. In MCF-7 
cells E2 reduces TGF-β signalling by promoting Smad ubiquitination and 
degradation. This activity of E2 does not require the DNA binding ability of 
ERα, but occurs through the formation of a protein complex of ERα with Smad 
and the ubiquitin ligase, Smurf1, which induces the enhancement of Smad 
ubiquitination and relevant degradation (Ito I, 2010). In other breast cancer 
cells instead, E2 was shown to modulate the stability of BRCA1, by inhibiting 
the proteasome degradation through an Akt dependent-phosphorylation of the 
protein.  
After 3h of E2 treatment, the decrease in SOCS2 protein levels I observed, 
involves a reduction of SOCS2 gene expression. Actinomycin D treatment was 
able to prevent the E2 effect on protein levels confirming a genomic 
involvement in E2 effect. Moreover the fact that E2 negative regulation of the 
GH inhibitor SOCS2 involves an initially rapid protein degradation maintained 
for a longer time by a decrease in its gene expression strengthens the 
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importance of this modulation by estrogens for osteoblast activity. It emerges 
that the estrogen-dependent operative state is a key element of the post-
receptor signaling machinery, which is central to the response of bone to GH 
activity. Moreover there is increasing evidence (Iglesias-Gato et al., 2013) that 
the responsiveness to GH depends upon circulating sex steroids levels. 
Interestingly the previous work of Leung showed that E2 inhibits STAT5 
phosphorylation through the up-regulation of SOCS2 expression, mechanism 
mediated by ER genomic activity, thus suggesting a tissue-specific action of E2 
on GH intracellular pathway. Hypothesis confirmed by our data in human 
primary fibroblasts, where we did not observe any modulation of SOCS2 levels 
after E2 treatment. 
 
5.2 GROWTH HORMONE AND SERMs IN hOBs 
Considering the widespread use in clinics of SERMs I tested  the effect of 
Raloxifene and Tamoxifen on GH signaling. Both SERMs showed a trend to  
decrease SOCS2 levels after 1h treatment, and to slightly increase GH-induced 
STAT5 phosphorylation however without reaching the significance. Moreover 
after 3h treatment of Raloxifene and Tamoxifen there is no modification in the 
expression of SOCS2. Our data suggest that, despite the estrogen agonist 
activity of SERMs in bone, Raloxifene and Tamoxifen do not exert the same 
positive effect on GH signaling as E2. This is not the first time that  SERMs in 
vitro do not act as pure estrogen agonists as expected. Tamoxifen was indeed 
shown to be both an agonist and antagonist of 17β-estradiol action in 
osteoblast-like cells (Fournier et al., 1996; Rao et al., 1996) or not to have the 
same power as E2 in inducing a biological response (Waters et al., 2001). 
Raloxifene was shown to activate mechanisms independent of ERE (Mark et 
al., 2000) in both estrogen receptor dependent and independent manners (Miki 
et al., 2009).   
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5.3 ISOLATION OF hMSCs AND VALIDATION OF GH 
ACTIVITY IN THIS MODEL 
Since GH receptors are expressed by bone marrow MSCs (Kassem et al., 1994), 
I recently started to study the possible GH modulation of MSCs commitment. 
Having demonstrated the positive modulation of GH signaling by E2 in hOBs, I 
investigated if the same interaction was present in MSCs. In the present thesis 
I report some preliminary data of this part of the project.  
I isolated human mesenchymal stromal cells from orthopedic waste material 
obtained after surgery, following a modified version of the protocol of Zhou and 
colleagues (Zhou et al 2008). As required by the criteria for the use of these 
cells as an in vitro model, the putative MSCs were tested for the expression of 
CD73, CD90, CD105 and committed to two lineages, the osteogenic and the 
adipocytic lineage. The number of positive cells for all the three markers in the 
5 different populations analyzed was ca the 46%. This result is in accordance 
with the view that bone isolated MSCs are a mixture of precursors at different 
stages and only a little pool is positive for all the CDs markers. Usually the 
50% are simply bipotent (Muraglia et al., 2000). Moreover data from our lab 
(data not shown), demonstrated that the expression profile of CD73, CD90, 
CD105 is different in the isolated stromal cells compared to that of human 
osteoblasts. The cells were then tested for their differentiation capability. When 
cultured in pro-adipogenic and pro-ostegenic media, the isolated cells were 
able to differentiate both to adipocytes and osteoblasts. 
After the characterization of the cells I investigated E2-GH interaction, showing 
that the enhancement of GH signaling and the decrease in SOCS2 levels 
mediated by E2 also occurred in hMSCs. Considering that bone marrow 
adipocytes are increased in number and size in GH deficient dwarf rats (Gevers 
et al., 2002), and the lack of information about GH action in stromal 
precursors, I evaluated GH action in the isolated hMSCs, focusing on its 
possible role in both osteogenesis and adipogenesis. The results showed that 
long term GH treatment increased significantly the transcription of OPG and 
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OSX,  and of RUNX2, although in this case not significantly, without affecting 
ADN and C/EBPα. RUNX2 is the master regulator of MSCs commitment 
towards the osteogenic lineage and it is considered one of the early osteoblastic 
genes. Therefore the lack of a significant increase after GH could be ascribed to 
an inadequate time schedule to evaluate it. In fact, after 14 days it is possible 
that RUNX2 signal could have already returned to basal level, however its 
action is apparent by the up-regulation of its downstream target genes. This 
hypothesis is in agreement with the observed up-regulation of the second 
master regulator of the osteogenic differentiation, OSX, which is downstream 
to RUNX2. The increase in OSX suggests GH involvement in MSCs 
commitment towards osteogenesis. OPG has been recently shown to be 
produced by stromal cells and to be necessary to trigger their osteogenic 
differentiation (ref). I was not able to evaluate GH effect in MSCs cultivated in 
osteoMEM, because the differentiating stimulus of the medium overcame GH 
effect (data not shown). Long term treatment with GH of hMSCs cultivated in 
adipoMEM induced a reduction in adipogenesis, quantified by a decrease in 
Oil-Red O accumulation and C/EBPα expression. The divergent data found 
about the modulation of C/EBPα and ADN by GH in growth and adipogenic 
media are not in contrast. In fact in growth medium hMSCs did nearly not 
express ADN and C/EBPα, therefore there is no need to reduce further their 
expression. On the contrary, in an adipogenic environment, in which the 
expression of these genes is highly stimulated, GH exerts its pro-osteogenic 
effect by inhibiting both ADN and C/EBPα expression. 
 
5.4 GROWTH HORMONE EFFECT ON MICRORNAS OF 
MSCs DIFFERENTIATION AND THE CROSS-TALK WITH E2 
A recent and new field of investigation concerns the role of microRNAs 
(miRNAs) in cellular function. They are short non-coding RNAs, ranging from 
18–25 nucleotides, that regulate gene expression by binding to the 3’-UTR (3’ 
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untranslated region) of the target mRNAs and inhibiting gene expression either 
by promoting degradation of the target mRNAs or avoiding their translation 
(Erson et al., 2008).  MiRNA expression patterns differ in progenitors or fully 
differentiated cells, suggesting that these miRNAs are highly relevant in MSC 
lineage committment.  
I therefore evaluated if the pro-osteogenic effect of GH on hMSCs involves the 
regulation of microRNAs. Indeed GH upregulated the two pro-osteogenic 
miRNAs investigated, namely miR-22 and miR-29c without affecting the pro-
adipogenic one, miR-204. MiR-204 is expressed in hMSCs and increases 
during adipogenic differentiation. Overexpression of miR-204 decreases RUNX2 
protein levels whereas the inhibition of the expression significantly elevates 
RUNX2 protein levels, suggesting that miR-204 acts as an endogenous 
regulator of RUNX2 in mesenchymal progenitor cells (Huang et al., 2010). 
MiR-22 highly and positively correlates with Body Mass Index (BMI) and is  
involved in BMP7 expression in cartilage  (Iliopoulos et al., 2008) In bone it 
inhibits HDCA6, the transcriptional inhibitor of RUNX2, thus favouring the 
MSCs osteogenic differentiation while inhibiting the adipogenic one (Huang et 
al., 2012). 
The osteogenic commitment is also promoted by the up-regulation of miR-29 
family, while it is negatively affected by their knocking down. Validated targets 
for miR-29 include several proteins that are inhibitors of osteoblast 
differentiation. Among the family, miR-29c and miR-29a were identified as 
target of Wnt, one of the main bone anabolic signals (Kapinas et al., 2009). The 
preliminary data obtained in this study suggest that the GH pro-osteogenic 
commitment of hMSCs could involve an up-regulation of specific pro-
osteogenic mi-RNAs, without affecting the one related to adipogenesis. 
Considering that also in hMSC E2 positively modulates GH intracellular 
signaling, I investigated if this enhancement could induce an increase in the 
microRNAs modulated by GH. Surprisingly the results showed that in cells 
pretreated with E2 there is no enhancing effect of GH on miR-22 and miR-29c. 
 Discussion 
 
 
 
84 
 
  
On the contrary E2 per se reduced miR-22 and miR-29c levels and was able to 
antagonize GH stimulatory effect. The inhibitory effect of E2 could also be 
observed on miR-204 levels. 
 
These results suggest that E2 might have an inhibitory effect on MSCs 
commitment towards adipogenic and/or the osteogenic lineage. The data could 
appear in contrast with the general idea that E2 drives osteogenesis, while 
inhibiting adipogenesis (Dang et al., 2002; Zhao et al., 2011). However, these 
E2 effects were described in MSC cultivated in specific differentiation media. A 
recent paper has shown that E2 favours hMSCs proliferation when cells are 
cultivated in normal growth medium and maintains the characteristics of 
MSCs, including cell surface markers, and osteogenic and adipogenic 
differentiation capacities (Hong L, 2011). Considering these data and the data I 
obtained, it seems that E2 could play a different role on the activity of GH on 
osteogenic cells depending on the stage of differentiation. It might preserve 
MSCs at an undifferentiated pool and it might promote osteogenic 
differentiation when cells are already committed. Further researches are 
needed to evaluate this hypothesis.    
 
 
5.5 CONCLUSIONS 
In conclusion the present study shows a new stimulatory effect of GH pathway 
by E2 in hOBs. From the data it emerges that the cross-talk between E2 and 
GH occurs not only systemically, but also in a cell-type-dependent manner. 
It was interesting to find that SERM, which are widely used in therapy instead 
of estrogens for their antagonistic activity in several tissues and agonistic 
activity in bone, were not able to increase GH pathway as estrogens in hOBs. 
This aspect should be considered when testing new SERM molecules. 
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Another interesting aspect is that in bone cells the effect of the interaction of 
these two hormones is different depending on the maturation stage of the cells. 
In hOBs there is an enhancement of both the intracellular pathway and of the 
GH responsive genes IG2, OPN, BSP expression, suggesting that GH and E2 
cooperate to activate the bone formation for the correct bone turnover. In 
hMSCs, there is a positive modulation of the intracellular pathway, however 
the pro-osteogenic effect of GH involving the upregulation of miR-22 and miR-
29c (important in the osteoblastic commitment of MSCs) is inhibited by the 
effect of E2 per se on miRNAs expression. The association GH-E2 thus results 
in a basal level of miR-22 and miR-29c, suggesting that the cells remain in an 
undifferentiated state (there are still ongoing experiments to further validate 
this hypothesis). The cell specificity of the effect of E2 to enhance JAK/STAT 
pathway activated by GH in hOBs through the inhibition of their negative feed-
back exerted by SOCS2 could open new opportunities for pharmacological 
investigations targeting SOCS2 in order to improve the anabolic action of GH 
in the bone.  
This research provides evidence for a regulatory interaction between estrogens 
and GH pathway at post receptor level and suggests that estrogens could 
improve the anabolic action of GH in bone and could influence the 
responsiveness to GH in GH deficient hypopituitary female. 
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